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Summary 
Background: 
Left ventricular (LV) function is an important predictor of outcome after cardiac 
surgery.  Severely impaired LV function (EF<20%) carries a 4-fold increase in the risk 
of in-hospital mortality compared to patients with EF >40%.   
Optimising LV function in the peri-operative setting may improve outcomes.  
Haemodynamic studies of permanent BiV pacing have reported a relative 25% increase 
in EF compared to dual-chamber right ventricular pacing. 
Methods: 
38 patients in sinus rhythm, ejection fraction ≤35%, undergoing on-pump 
cardiac surgery were enrolled into the main study.  All patients received temporary 
pacing wires attached to the right atrium, right ventricular outflow tract and left 
ventricle.   
Patients were randomly assigned to post-operative biventricular pacing or atrial-
inhibited/dual-chamber right ventricular pacing.  The primary endpoint was the 
transition from level 3 to level 2 care.     
The cardiac output measurements obtained using the PA catheters were 
compared to simultaneous measurements obtained from a FloTrac device (Edwards 
Lifesciences, arterial pulse-wave analysis).  The measurements were compared using a 
Bland-Altman analysis.  
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Results:  
The median duration of level 3 care was 22.0 (IQR: 16.0-66.5) hours and 37.5 
(IQR: 16.3-55.0) hours in the BiV and standard pacing groups respectively (log-rank 
p=0.58, 95% CI: 0.43-1.61).   
At 18 hours, cardiac output with biventricular pacing (5.8 L/min) was 9% higher 
than dual chamber right ventricular pacing (5.3 L/min), ( p=0.001).  Optimisation of the 
VV interval produced a further 4% increase in cardiac output (p=0.005).      
Analysis of the cardiac output measurements taken simultaneously from the PA 
catheter and FloTrac system yielded a bias -0.33L/min±2.2 L/min and a percentage 
error of 42%.    
Conclusions: 
Patients who require post-operative pacing or a prolonged haemodynamic 
support after surgery may benefit from optimised BiV pacing.  However, for the 
majority of patients BiV pacing does not alter the clinical outcome compared to atrial-
inhibited or dual chamber RV pacing. 
Although the FloTrac system is easy to use and rapidly reports changes in 
cardiac output, its precision requires refinement before it can be used instead of a PA 
catheter.  
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1.1 Introduction 
 Coronary artery disease is the leading cause of heart failure in the United 
Kingdom with a prevalence of 2% in the general population and 7.5% in patients over 
the age of 75 years (1-3) .  Heart failure patients may benefit from surgical 
revascularisation especially in the context of left main stem or proximal left anterior 
descending coronary artery disease and viable myocardium (4).  
A meta-analysis of 24 trials of patients with multi-vessel coronary artery 
disease, impaired left ventricular (LV) function and myocardial viability, reported a 
79.6% reduction in mortality with surgical revascularisation compared to optimal 
medical therapy at 25±10 months follow up (3.2% v 16%; Chi
2
=147, p<0.0001) (4).  
Viability was analysed using dobutamine stress echocardiography, position-emission 
tomography or cardiac magnetic resonance imaging.  A multivariate analysis also 
demonstrated a relationship between pre-operative LV ejection fraction (EF) and the 
prognostic benefit from surgery.  Patients with significant LV dysfunction achieved the 
greatest improvement in prognosis compared to lesser degrees of LV impairment.    
There was no prognostic benefit with surgery in the absence of viability.  
  However, patients with severe LV systolic function (EF <20%) are at increased 
risk of in-hospital complications after surgery compared to patients with EF >40%.  The 
New York State Database contains information on over 55,000 patients who had 
surgery between 1997-9 (5).  Patients with EF <20% had a 3-fold increase in the risk of 
respiratory failure, and a 4-fold increase in renal failure, sepsis and in-hospital mortality 
compared to patients with EF >40%.  The discharge-to-home rates were lower in the EF 
<20% group compared to EF >40% group (73.1% v 87.7%; p <0.001).  Therefore, 
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treatments directed at optimising peri-operative LV function may potentially improve 
outcomes in this high risk surgical group. 
 The European System for Cardiac Operative Risk Evaluation (EuroSCORE) has 
identified risk factors for mortality after cardiac surgery.  Data was obtained from 
almost 20,000 patients, across 128 surgical units in different 8 countries in 1995 (add 
ref roques F).  The odds ratios (OR) for mortality increased with progressive LV 
dysfunction, EF 30-50% (OR 1.5; standard error 0.138; p <0.001) and EF <30% (OR 
2.5; standard error 0.340; p <0.001).  Both databases have identified that LV 
dysfunction increases the risk of cardiac surgery.  However, other baseline 
characteristics including: age, female gender, creatinine >200 µmol/L, extra-cardiac 
arteriopathy, lung disease, neurological dysfunction, PA pressure, pre-operative state 
and the nature of the operation need to be combined with LV function to calculate the 
patients’ operative risk.  This may explain why the EuroSCORE predicts a lower 
mortality based on the published odds ratios compared to the New York database.   
 During on-pump cardiac surgery the myocardium is arrested with a mixture of 
blood and cardioplegia solution with mechanical circulatory support.  Although 
cardioplegia solution and volatile anaesthetic agents protect the heart during surgery, the 
protection is not perfect and the heart is subjected to an ischaemia-reperfusion (IR) 
injury.  All patients develop a systemic inflammatory response (SIR) syndrome that 
may compromise organ-perfusion if severe or prolonged.   
The next sections discuss IR and the SIR syndrome in more detail along with the 
conventional treatments for low cardiac output including inotropes and intra-aortic 
balloon pumps and vasoconstrictors to attenuate the SIR syndrome.  These treatments 
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do have limitations and biventricular pacing after cardiac surgery may benefit such 
patients with low cardiac output following surgery.     
 
1.1.1 Peri-operative management of heart failure medications  
  ACE-inhibitors (ACE-I), β blockers and aldosterone antagonists improve heart 
failure symptoms, LV ejection fraction and prognosis in heart failure patients (2, 6-11).  
The SOLVD (Studies of LV Dysfunction) group reported a 16% relative reduction in 
death at 40 months follow up, in heart failure patients (NYHA II/III) with EF <35%, 
taking enalapril v placebo (35.2% v 39.7%; p=0.004) (12).  Pitt et al reported a 30% 
relative risk reduction in mortality with spironolactone compared to placebo at 24 
months in patients with heart failure (EF <35%) treated with an ACE-I (mortality 35% v 
46%; p <0.001 respectively) (6).  The prognostic benefits of β blockers was also 
demonstrated in the CIBIS II trial (Cardiac Insufficiency Bisoprolol Study II) (13).  
This trial reported a 5.5% absolute risk reduction with bisoprolol v placebo at 1.3 years 
follow up in symptomatic heart failure patients (NHYA III/IV) with EF <35%, treated 
with ACE-I (11.8% v 17.3%; p <0.0001 respectively). 
 Although these therapies are well established for the treatment for chronic heart 
failure, they are often discontinued before cardiac surgery.  ACE-I and aldosterone 
antagonists may increase the risk of peri-operative hypotension and subsequent 
vasoconstrictor requirements.  There is limited evidence to support this argument.  One 
study of 40 patients reported that stopping the ACE-I before surgery did not prevent 
post-operative hypotension (14).  β blockers are usually continued before surgery 
especially in patients with a recent myocardial infarction or impaired LV systolic 
function.  
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1.1.2 Systemic Inflammatory Response syndrome after cardio-pulmonary bypass 
Cardiac surgery stimulates an aggressive inflammatory response by activating 
cytokines, complement and other modulators of inflammation (15).  A report from the 
Society of Thoracic Surgeons National Database found that 20% of low risk patients 
developed a post-operative systemic inflammatory response syndrome (SIRS) (16).  
11% developed multi-organ dysfunction syndrome, which carried 41% mortality (17).  
Acquired multi-organ dysfunction syndrome was the best predictor of mortality in 
cardiac surgical patients who required prolonged ventilation (17).  To diagnose the 
systemic inflammatory response syndrome, 2 or more of the following criteria must be 
achieved: 
 Temperature: >38°C or <36°C 
 Heart rate:  >90 beats/min 
 Respiratory rate: >20 breaths/min or PaCO2 <32 mmHg 
 Leukocytes: >12,000, <4,000/mm3 or  >10% immature forms 
The SIR syndrome can be activated through a variety of mechanisms including 
tissue trauma, blood transfusion, hypothermia, cardio-pulmonary bypass, mechanical 
ventilation, ischaemia-reperfusion injury during aortic cross-clamping, and sepsis (18-
20).  Patients with impaired LV function and diabetes appear to have more pro-
inflammatory cytokine release, which increases the incidence of post-operative 
complications (21, 22).   
Cardio-pulmonary bypass induces mediators of inflammation, including IL-6, 
which are associated with myocardial stunning, ischaemia and β-adrenergic receptor 
desensitisation (23).  TNF-α, IL-1β and IL-6 are associated with myocyte refractoriness 
to adrenergic stimulation after cardio-pulmonary bypass.  LV wall motion abnormalities 
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and ischaemic episodes correlate with IL-6 and IL-8 concentrations (23, 24).  Pro-
inflammatory cytokines also increase nitric oxide production via iNOS (nitric oxide 
synthase) which has been shown to depress myocardial contractility (25).   
The SIR syndrome is also associated with acute lung injury, pleural effusions, 
stroke (1-3%) and seizures (5-10%), renal insufficiency requiring haemofiltration (1%), 
hepatic injury and activation of the clotting cascades (19, 20, 26-30).    
Anaesthetic agents, including propofol and sevoflurane, opiates and 
haemofiltration have anti-inflammatory properties and help down-regulate the SIR 
syndrome (31-33).  Haemofiltration can remove mediators of inflammation, including 
TNF-α and IL-1β from the circulation (34, 35).  Other possible treatments include: the 
use of off-pump cardiac surgery, heparin-coated bypass circuits, leukocyte filters, and 
anti-inflammatory agents including serine protease inhibitors, aprotinin, anti-oxidants, 
corticosteroids and cyclooxygenase inhibitors.  However, there is limited evidence to 
support these therapies.     
 
1.1.3 Ischaemia-reperfusion injury after cardiac surgery 
The concept of the ischaemia-reperfusion injury was first described by Jennings 
et al, in the 1960s (36).  Jennings observed that reperfusion, after ligation of a canine 
coronary artery was associated with accelerated myocardial necrosis on histological 
samples.  The necrosis observed after 30-60 minutes of reperfusion was similar to that 
observed, 24 hours after permanent occlusion of a coronary artery.    
Ischaemia-reperfusion injury after cardio-pulmonary bypass is associated with 
stunning injury after reperfusion of the ischaemic myocardium (37). Ischaemia induces 
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the accumulation of intra-cellular sodium, hydrogen and calcium ions, culminating in 
tissue acidosis (38).  Subsequent reperfusion reverses this flux in ions with rapid 
correction of the cellular acidosis leading to enhanced cytotoxicity (39, 40).  High 
sodium concentrations increase sarcoplasmic reticular calcium, leading to calcium over-
load, myofibrillar hyper-contraction, adenosine triphosphate depletion, structural 
damage to mitochondria and myocardial stunning (41, 42).  Calcium over-load leads to 
the production of reactive oxygen species from the mitochondria, which triggers cellular 
injury.   
Endothelial nitric oxide is released during IR injury.  Nitric oxide is normally a 
vaso-protective agent, leading to vasodilation and preventing platelet aggregation.  
However, in high concentrations, nitric oxide paradoxically potentiates the toxic effects 
of the reactive oxygen species leading to further IR injury. 
 Cardioplegia solution mixed with cold-blood is designed to reduce the ischaemic 
injury during cardiac surgery.  This potassium-rich solution reduces myocardial 
metabolism and oxygen consumption during this vulnerable period.  IR after cardiac 
surgery may manifest as arrhythmias, low-output states, peri-operative myocardial 
infarction or myocardial stunning.  Inotropic agents are required after surgery to 
increase cardiac output and prevent low-output states. 
 
1.1.4 Inotropes 
Inotropes are used to increase cardiac output especially in the critical first 6 
hours after surgery.  A study by Lalu et al, identified a nadir in LV stroke work at 3 
hours after surgery in 15 patients with no prior history of myocardial infarction and 
normal pre-operative LV systolic function (43), see figure 1. 
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Figure 1: LV stroke work index before cardioplegia and after reperfusion. 
 
*= p<0.01 compared to pre-operative LV stroke work index.  Adapted from Lalu et al, 
2005 (43). 
  In clinical practice, inotropic agents are used in combination with 
vasoconstrictors to increase cardiac output and mean arterial pressure, and intra-aortic 
balloon pumps (IABP) to increase cardiac output, coronary perfusion and to reduce 
after-load, following bypass surgery.    
Inotropes are used to increase cardiac output in the peri-operative period.  
Inotropes recruit stunned-reperfused myocardium to contract.  Although not an ideal 
strategy to counter IR injury, inotropes are not associated with worse functional 
recovery or increased tissue necrosis after surgery (44).   
In heart failure patients, phosphodiesterase inhibitors (PDE-III) including 
enoximone and milrinone are routinely used after cardiac surgery.  The PDE-III agents 
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have a positive inotropic effect by increasing intramyocardial levels of cAMP, promote 
vasodilatation and reduce systemic and pulmonary vascular resistance but at the 
expense of increasing myocardial oxygen demand (45-48).   
A study of 99 patients receiving elective cardiac surgery, reported after a 50 
µg/kg bolus of milrinone, cardiac index increased by 54% in patients with low pre-
operative cardiac index (<1.6L/min/m
2
; p <0.05).  Milrinone reduced pulmonary 
vascular resistance (PVR) by 26% after a 60 minute infusion (0.75-0.75 µg/kg/min) in 
patients with elevated pre-operative PVR >200 dynes.sec.cm
-5
 compared to baseline 
measurements before milrinone infusion (p <0.005)
 
(49, 50).  In another study of 44 
patients with an EF >30%, milrinone increased graft flow by 48% in venous conduits 
and FAC (%) on TOE (+3% v -7%; p=0.002) 10 minutes after bypass compared to 
baseline v placebo (51).   
Enoximone has been reported to reduce post-operative TNI levels compared to 
dobutamine.  In a non-randomised study of 216 patients, 70% with preserved LV 
function, enoximone reduced troponin I levels >50% at 12 hours compared to 
dobutamine (p =0.003) (52).   
 
1.1.5 Intra-aortic balloon pump 
 An alternative method of optimising peri-operative cardiac output is to insert an 
intra-aortic balloon pump (IABP).  IABPs improve coronary perfusion, protect against 
myocardial ischaemia and augment cardiac output by reducing after-load.  This device 
may be inserted before or after surgery and in combination with inotropes and 
vasoconstrictors.      
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A propensity matched analysis of 478 pairs of high risk surgical patients with a 
Euroscore >8, reported that patients without an IABP had 64% increased risk of in-
hospital mortality (p=0.001), 45% higher risk of peri-operative MI (p=0.01), and 45% 
risk of a longer ITU admission (p=0.001) compared to patients with an IABP  (53).  
IABP increased mean flow in the arterial mammary grafts by 18% and by 10% in vein 
grafts (p=0.04) (54).   
A meta-analysis of 110 papers on the peri-operative utilisation of IABP has 
recommended the routine use of IABP for patients with 2 of the following: EF <30-
40%; left main stem disease; unstable angina or re-do operation (55).   
Despite these potential advantages, IABPs have an associated 4% risk of 
vascular complications including limb ischaemia or groin haematoma from the device 
(56, 57).  The device also requires the patient to remain immobile in bed and as an 
indwelling device is a potential source of infection.  These factors limit the clinical 
application of this device.   
 Inotropes and IABP are both used in routine clinical practice to wean patients 
from cardio-pulmonary bypass and improve cardiac output after surgery.  Although 
these methods are effective, they have several drawbacks including: increased 
myocardial oxygen demand and vascular complications.  This has created interest in 
temporary biventricular (BiV) pacing for acute haemodynamic support after separation 
from cardio-pulmonary bypass (CPB).  If BiV pacing can augment cardiac output by 
reversing electro-mechanical dyssychrony after surgery, it may reduce the requirements 
for inotropes and IABP.  In practical terms this can be achieved by upgrading the 
conventional temporary dual chamber epicardial pacing system implanted before 
weaning from CPB with the addition of LV pacing wires.  
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1.1.6 A brief history of biventricular pacing 
 Biventricular (BiV) pacing has been investigated as a heart failure treatment for 
over 40 years (58).  Pioneering work by Cazeau et al in the 1990s (59) led to it being 
established as a therapy to improve prognosis in chronic heart failure patients with 
dyssynchrony (60).  Multi-centred randomised controlled trials focused on long-term 
outcomes including LV remodelling and mortality (60, 61); however BiV pacing also 
has an acute haemodynamic effect.  Previous trials have reported an absolute increase in 
ejection fraction of 25% (see section 1.3).  This has been demonstrated by conducting 
acute haemodynamic studies in patients receiving a permanent BiV pacing system (2, 
62, 63).   
This principle can be applied to patients after cardiac surgery by attaching 
pacing wires to the right atrium, right ventricle and left ventricle before separation from 
the cardio-pulmonary bypass circuit.  Therefore, temporary BiV pacing can be 
performed in the post-operative setting with the aim of improving cardiac efficiency, 
acute haemodynamic function and may reduce the length of ITU admission, in patients 
with severe LV systolic dysfunction. 
The following sections of this review will focus on electromechanical 
dyssynchrony as a potential target for BiV pacing, the acute haemodynamic effects of 
BiV pacing, including previous trials of BiV pacing after cardiac surgery, and the 
potential benefits of optimising the AV and VV timing intervals. 
 
1.2 Dyssynchrony   
The term dyssynchrony is used to describe the inefficient and in-coordinated 
filling and contraction of the heart.  The normal heart is composed of myocardial fibres 
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with a longitudinal orientation in the sub-endocardium and epicardium and 
circumferential orientation in the mid wall.  During systole there is both circumferential 
and longitudinal contraction with shortening from the base to the apex of the LV. This 
complex matrix of myocardial fibres is activated in a temporal order by the His-Purkinje 
network which achieves optimal pump efficiency.  A wave front of electrical 
depolarisation starts at the endocardial surface of the heart at the apex of the LV and 
spreads towards the base of the LV and the epicardium.  This wave-front of electrical 
depolarisation takes 80-100 ms to disperse through the LV (64).    
The following sections review the literature on electro-mechanical dyssynchrony 
and the utility of identifying dyssynchrony to predict a response to BiV pacing.   
   
1.2.1 Electrical dyssynchrony– QRS duration and morphology 
LBBB is a significant predictor of LV systolic dysfunction, mortality and 
response to BiV pacing in patients with heart failure (65-67).  The MADIT-CRT trial 
investigated the response to BiV pacing in heart failure patients with mild symptoms 
(NYHA I-II), severe LV systolic dysfunction (EF <30%) and QRS duration >130 ms 
(61).  A post-hoc analysis of the trial compared the primary outcome of death or heart 
failure hospitalisation in patients receiving CRT-D v ICD-only with respect to their 
baseline QRS morphology (68).  The subgroup with LBBB had a 53% reduction in the 
primary endpoint with CRT-D v ICD-only (p <0.001) whereas there were no beneficial 
effects in the non-LBBB subgroup (HR 1.24; p=0.257).  Fewer ventricular arrhythmias 
were observed in the LBBB group and LV end-systolic volumes were reduced 
compared to the non-LBBB subgroup.  
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In contrast, there are limited data to support the routine implantation of BiV 
pacemakers in subjects with a narrow QRS duration (<120 ms).  The majority of studies 
reporting a clinical benefit are small, single-centre studies with limited follow up (69-
71).  Achilli et al investigated 52 patients with NHYA 3-4 symptoms, EF <35% and 
either an inter-ventricular mechanical delay >20ms or intra-ventricular dyssynchrony 
(71).  Intra-ventricular dyssynchrony was defined as the onset of the diastolic E wave 
before maximal apical displacement of the basal lateral LV wall.  Only 14 patients had a 
QRS duration ≤120 ms.  BiV pacing increased the QRS duration by 10 ms (p=NS) but 
BiV pacing reduced NHYA class (3.3±0.5 v 1.7±0.6 at baseline v 6-months; p <0.001) 
and increased 6 minute walk distance (276.4±88.9m v 369.9±70.2m; at baseline v 6-
months; p <0.01) in patients with QRS duration ≤120 ms.   
Bleeker et al studied the effects of BiV pacing in 33 heart failure patients, 
NHYA 3-4, QRS <120 ms, EF <35% with a septal to lateral wall delay of at least 65ms, 
to peak systolic velocity using TDI (70).  A control group of 33 patients with QRS >120 
ms was created and both groups followed up for 6 months.  Improvements of equal 
magnitude were observed in both groups: reduction in LV dyssynchrony (68±37 ms v 
78±39 ms; p=NS); improvement in 6 minute walk distance (89±107 m v 130±95 m; 
p=NS) and improvement in EF (8±8 % v 9±7 %; p=NS).  The comparisons are for 
variables measured at 6 months compared to baseline values in the narrow QRS v wide 
QRS duration groups respectively.             
The ESTEEM-CRT (Evaluation of CRT in narrow-QRS patients with 
mechanical dyssynchrony from a multicenter study) included 68 patients with NYHA 
class III heart failure, QRS <120 ms, LVEF <35% and intra-ventricular dyssynchrony.  
Dyssynchrony was assessed using a 12 segment model of the LV and calculating the 
standard deviation of time to peak systolic velocity, using TDI (72).  After 6 months 
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follow up, BiV pacing improved NYHA score and quality of life score (p <0.01 for both 
comparisons) but there was no statistically significant improvement in peak V02 or 
reduction in LV volumes or improvement in ejection fraction.   
The ‘Cardiac resynchronisation therapy in heart failure with narrow QRS 
complexes’, RETHINQ trial investigators studied the effect of BiV pacing in 172 
patients with a standard indication for an ICD (73). The patients were randomised to 
receive either BiV pacing with ICD or ICD-only (control group).  Enrolment included 
NYHA class III patients with EF ≤35%, QRS <130 ms and mechanical dyssynchrony.  
The primary endpoint was a ≥1 ml/kg/min increase in peak oxygen consumption during 
cardio-pulmonary exercise testing after 6 months. The primary endpoint was not 
significantly different between the 2 groups at the end of the study, neither was there a 
significant difference in 6 minute walk time, LV volumes or quality of life score.  The 
only significant finding was an improvement in NYHA score in the BiV group v control 
(54% v 29%, p =0.006).   
A pre-specified analysis of outcome was performed for subject with QRS ≥120 
ms v <120 ms.  Peak oxygen consumption increased in the QRS ≥120 ms group (p 
=0.02) but not in the QRS <120 ms group (p =0.45).  Therefore, patients with prolonged 
QRS durations above 120ms and with LBBB morphology are most likely to benefit 
from BiV pacing. 
BiV pacing is an effective therapy to improve heart failure symptoms, exercise 
capacity and promote LV remodelling in patients with severe LV systolic impairment 
and prolonged QRS durations (2, 74).  Therefore, this group of patients may also benefit 
from post-operative BiV pacing after cardiac surgery.        
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1.2.2 Non-responders to BiV pacing 
The 12-lead ECG is a useful tool for identifying electrical dyssynchrony and a 
prolonged QRS duration has been used as a selection criterion in previous trials of BiV 
pacing, see table 1.  However, clinical trials consistently report a non-response rate to 
BiV pacing in the region of 25-30%.   
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Table 1: Inclusion criteria for randomised control trials of BiV pacing. 
Trial n NYHA 
class 
LVEF 
(%) 
LVEDD 
(mm) 
SR/AF QRS criteria 
(ms) 
MUSTIC-SR (75) 58 III ≤35% ≥60 SR ≥150 
MIRACLE (76) 453 III,IV ≤35% ≥55 SR ≥130 
PATH-CHF (77) 41 III,IV ≤35% NA SR ≥120 
MIRACLE-ICD 
(78) 
369 III,IV ≤35% ≥55 SR ≥130 
CONTAK CD (79) 227 III,IV ≤35% NA SR ≥120 
MIRACLE ICD II 
(80) 
186 II ≤35% ≥55 SR ≥130 
PATH CHF II (81) 89 III,IV ≤35% NA SR ≥120 
COMPANION (82) 1520 III,IV ≤35% NA SR ≥120 
CARE-HF (60) 814 III,IV ≤35% ≥30 SR ≥150 or 
≥120+echo. 
REVERSE (83) 610 I,II ≤30% ≥55 SR ≥120 
MADIT-CRT (84) 1800 I,II ≤30% NA SR ≥130 
RAFT (85) 1800 II,III ≤30% >60 SR/AF ≥130 or paced 
≥200 
AF=atrial fibrillation 
SR=sinus rhythm 
 
The mechanisms of non-response to BiV pacing are multi-factorial.  The level of 
functional block is variable in LBBB and dyssychrony may be limited if it occurs at the 
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terminal fibres of the conduction system.  However, patients with narrow QRS 
complexes exhibit mechanical dyssynchrony with a prevalence of 30-50% (86-88), 
indicating a sub group of patients that may potentially benefit from BiV pacing.  In 
addition, 30-40% of patients with QRS >120 ms have no evidence of mechanical 
dyssynchrony which may explain the non-response rate to BiV pacing in patients with 
QRS >120 ms. 
Sub-optimal LV pacing is important.  Apical and anterior LV locations are sub-
optimal and targeting the region of latest LV activation may improve response rates (89-
91).  Non-viable myocardium causes conduction delay and is detrimental to 
resynchronisation, especially if it is present in the basal posterior/lateral LV region, at 
the preferable site of LV pacing.   Enlargement of the left atrium is an adverse marker of 
response to BiV pacing especially if it is associated with atrial arrhythmias.  Finally, for 
effective LV resynchronisation, a high percentage of BiV pacing (ideally 100%) is 
required.  Atrial arrhythmias, ventricular ectopy and LV lead failure can inhibit BiV 
pacing leading to non-response (61, 68, 89, 92).   
Acute changes in LV after-load can also cause dyssynchrony, even in the 
presence of normal electrical conduction.  In a canine study, clamping the aorta 
increased after-load, prolonged LV relaxation time and regional shortening became 
dyssynchronous (93).  These findings were supported by Wang et al, demonstrating that  
reducing after-load with diuretics and vasodilators reversed dyssynchrony in heart 
failure patients (94).  In the absence of electrical dyssynchrony, BiV pacing is 
ineffective at reversing this load-dependent mechanical dyssynchrony.  This is another 
potential explanation for the reported non-responder rate to BiV pacing.     
18 
 
Echocardiography and CMR techniques have been developed to analyse 
mechanical dyssynchrony in an attempt to refine the selection criteria for BiV pacing 
and reduce the non-responder rate.  Mechanical dyssynchrony can be observed between 
the atria and ventricles, between the left and right ventricle and within the left ventricle- 
AV, inter- and intra-ventricular dyssynchrony respectively (95).  In reality, heart failure 
patients may develop all 3 types of mechanical dyssynchrony to varying degrees of 
severity. 
 
1.2.3 Intra-ventricular dyssynchrony 
Patients with heart failure may develop regional conduction delays that alter the 
pattern of myocardial depolarisation and reduce stroke volume.  Left bundle branch 
block (LBBB) is a marker of delayed electrical activation and is present in 15-27% of 
heart failure patients  (96).  Although there is heterogeneity in the pattern of LV 
contraction in patients with LBBB, the left basal postero-lateral wall is most frequently 
the site of late activation.  The right antero-septal wall is activated rapidly by the intact 
right bundle and contracts early but the contralateral wall is quiescent.  The basal 
postero-lateral wall contracts in late systole/early diastole against a relaxing septum.  
This inefficient pattern of contraction delays the rise in intra-cavity pressure (dP/dTmax); 
reduces ejection fraction by 23%; reduces regional coronary blood flow by 11-19% and 
myocardial metabolism (97, 98).  Late activation of the postero-lateral papillary muscles 
distorts mitral valve closure and results in mitral regurgitation.  
Intra-ventricular dyssynchrony can be assessed using TDI, (figure 2).  In this 2 
segment model, tissue velocities are measured at the basal septum and lateral walls.  
19 
 
The difference in time to peak systolic velocity is the measurement of intra-ventricular 
dyssynchrony.   
Although it appears logical that intra-ventricular dyssynchrony would be more 
prevalent in patients with broad QRS widths, a study by Bleeker et al failed to identify a 
relationship (99).  A time delay of  >60 ms between peak velocity of the basal septum to 
lateral wall was used to define mechanical dyssynchrony, (table 2 and figure 2).  In a 
sample of 90 subjects with heart failure and severe LV systolic dysfunction using linear 
regression analysis, there was no correlation between electrical and intra-ventricular 
mechanical dyssynchrony.  
 
Figure 2: Measurement of intra-ventricular dyssynchrony- Time to peak velocity in the 
septal (yellow) and lateral walls (green) for 3 cardiac cycles. 
 
 
  
Basal septum-lateral wall delay. 
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Table 2: Relationship between electrical and intra-ventricular dyssynchrony. 
QRS duration /ms  Mechanical dyssynchrony/% 
<120   27 
120-150  60 
>150  70 
 
A study by Turner et al investigated the activation patterns of the LV free wall in 
patients with LBBB compared to narrow QRS durations and severe LV systolic 
dysfunction. (100).  LV free wall activation was prolonged in the LBBB group 
compared to the narrow QRS group (155±23 ms v 65.5±25 ms; p =0.05). However, late 
activation of the LV free wall was observed in the narrow QRS group and LV 
synchronicity could be improved with BiV and LV pacing, see figure 3.  
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Figure 3:  The synchronicity index at baseline and during LV and BiV pacing.  LV 
synchronicity index is improved in both patient groups and with both pacing 
modes.   
 
Adapted from Turner et al, Circulation 2004 (100).  
 
1.2.4 Inter-ventricular dyssynchrony 
 In healthy individuals, the LV is activated before or at the same time as the RV.  
A delay in LV activation has been observed in patients with LBBB and reverses this 
relationship (101).  In a study by Grines et al, the pattern of septal wall motion was 
studied in 18 patients with preserved LV function and QRS >120ms with LBBB 
morphology (101).   
LBBB delayed LV activation by 85 ms compared to normal subjects (p <0.001).  
The times to aortic valve opening and closing and mitral valve opening were also 
delayed in the LBBB group.  However, the times to mitral valve closure remained 
constant due to a high proportion of 1
0
 AV block in the LBBB group.  Therefore, LV 
filling time was reduced in the LBBB group, reducing pre-load and stroke volume.  The 
22 
 
duration of LV isovolumic relaxation was also prolonged (94±31 ms v 36±20 ms in 
healthy subjects; p <0.0001), see figure 4. 
Figure 4: Timing of mechanical events in normal patients (A) and LBBB (B). 
 
In the normal group, LV events occurred before or at the same time as the RV.  This 
relationship was reversed in patients with LBBB.  po, to, ao and ao are time of pulmonary, 
tricuspid, aortic and mitral valve opening and pc, tc, ac and ac time of valve closure, 
respectively.   Adapted from Grines et al, (101). 
LBBB also changed the motion of the inter-ventricular septum.  Early RV filling 
displaced the septum into the LV and impeded LV filling.  RV ejection occurred during 
LV isovolumic contraction and displaced the septum towards the RV.  LV systole 
continued after pulmonary valve closure which displaced the septum towards the RV.  
In diastole, the tricuspid valve opened before the mitral valve displacing the septum 
towards the LV with a similar pattern with atrial contraction.   
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Therefore, in patients with LBBB there are several oscillations of the inter-
ventricular septum during systole and diastole, hence the term inter-ventricular 
mechanical dyssynchrony (IVMD).   LBBB reduced LV ejection fraction compared to 
the control group (40±16% v 67±7; p <0.001).  BiV pacing is a therapeutic option to 
reset the timing of filling, contraction and relaxation and reverse IVMD. 
Abnormal septal wall motion has also been reported after sternotomy.  In an 
animal study, septal wall motion was observed in 11 pigs, after induction of anaesthesia 
and sternotomy. Wall motion was recorded, both with the pericardium open and closed 
and after closing the chest with the pericardium closed and then subsequently re-opened 
(102).   
Closing of the pericardium, while the chest wall was open, reduced stroke 
volume by 19% (p <0.05).  Systemic vascular resistance increased by 19% with the 
chest wall and pericardium both closed (p <0.05).  These effects were reversed by re-
opening the pericardium.  Chest wall closure resulted in a paradoxical motion of the 
inter-ventricular septum with the pericardium open or closed.  Closing the pericardium 
reduced stroke volume due to the external constraint of the pericardium.     
The pattern of septal wall motion is also altered in the presence of RV pressure 
overload (103).  The pattern of septal wall motion was studied in 20 children with 
congenital heart disease and raised RV pressures and compared to 29 control subjects.  
Elevated RV pressures (>50% systemic pressure) reduced septal curvature, which was 
most prominent at the end of systole.  Therefore, elevated RV pressure also affects 
septal wall motion.      
     The inter-ventricular mechanical interval can be measured using pulsed wave 
Doppler in the outflow tract of both ventricles (figure 5).  Pulsed wave Doppler is 
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obtained from both the LV and RV outflow tract.  The inter-ventricular mechanical 
interval is calculated by subtracting the LV to RV pre-ejection intervals.  This 
measurement has been used as part of the enrolment criteria in large randomised control 
trials of BiV pacing including the CARE-HF study (60).  
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Figure 5: Measurement of inter-ventricular mechanical interval (B-A) using pulsed 
wave Doppler.  A: Pulmonary pre-ejection interval and B: Aortic pre-ejection time. 
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1.2.5 Diastolic (AV) dyssynchrony 
 There are 4 phases of diastole: isovolumic relaxation; rapid filling; slow filling 
(diastasis) and atrial contraction.  In healthy hearts, LV filling occurs at low LA 
pressure into a compliant LV but elevated filling pressures are the principal 
consequence of diastolic dysfunction.  An LVEDP >16mm Hg or pulmonary capillary 
wedge pressure >12 mm Hg are used as reference values to define raised LV filling 
pressures (104).   
 Filling pressures depend on LV compliance and loading conditions.  Compliance 
is affected by myocardial fibrosis, chamber geometry and wall thickness, and extrinsic 
factors including external pericardial constraint and diastolic ventricular interaction.  
Increased after-load delays myocardial relaxation and also increases LV filling 
pressures.     
 Echocardiography can be utilised to assess diastolic filling (figure 6).  To 
maximise LV filling/pre-load, atrial contraction should occur after a period of early LV 
filling and before the onset of LV contraction.  Prolongation of the AV interval, which 
can also be indicated by first degree AV block on a 12-lead ECG, truncates early filling 
due to the premature onset of atrial contraction and blood refluxes back through the 
mitral valve during diastole (105).  A pathologically short AV interval truncates atrial 
filling with the abrupt onset of LV contraction.   
 Prolongation of the PR interval is a common problem.  35% of heart failure 
patients have a PR interval >200 ms.  A study of pacing after on-pump cardiac surgery 
reported that 38% of patients had PR interval >200 ms after separation from the bypass 
circuit (106).  Reversing AV dyssynchrony using an AV optimisation protocol 
increased cardiac index by 20% compared to intrinsic rhythm (140ms v 220 ms 
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respectively).  The greatest benefit was observed in patients with significant LV systolic 
impairment.   
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Figure 6: Patterns of LV filling with optimal and sub-optimal AV intervals.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
    
E 
A 
Optimal LV filling with distinct E 
(early) and A (atrial) waves.  
Sub-optimal LV filling with a 
prolonged AV delay with 
truncation of the E wave and 
diastolic MR (shaded-inverted 
triangle).  
Sub-optimal LV filling with a 
short AV delay with truncation of 
the A wave and early mitral valve 
closure (dashed line).  
Mitral valve closure 
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1.2.6 The utility of mechanical dyssynchrony- The PROSPECT trial 
 A multi-centre prospective trial was conducted to assess the utility of 
mechanical dyssynchrony to predict a response to BiV pacing.   Twelve measurements 
were performed for each patient with standard indications for BiV pacing including EF 
≤35% and QRS ≥130 ms.  The markers of dyssynchrony showed only modest value in 
both sensitivity and specificity in predicting a response to BiV pacing using both a 
clinical composite endpoint (table 3) and ≥15% reduction in end-systolic volumes. 
Table 3: The predictive value of each individual marker of mechanical dyssynchrony in 
predicting a response to BiV pacing using the composite clinical score.  Adapted from 
the PROSPECT trial. 
Marker Yield/% Sensitivity/% Specificity/% AUC p for 
AUC 
SPWMD 71.0 55.4 50.0 0.54 0.27 
IVMD 92.4 55.2 56.4 0.59 0.013 
LPEI 94.6 66.3 47.1 0.6 0.001 
Ts-(L-S) 66.8 42.4 57.0 0.5 0.85 
Ts-SD 50.0 74.1 35.3 0.6 0.024 
Ts-peak 82.0 51.9 53.8 0.55 0.19 
Key:  
SPWMD- septal to posterior wall mechanical delay ; IVMD- inter-ventricular mechanical delay; 
LPEI- LV pre-ejection interval; Ts-(L-S)- time delay from septal to lateral wall peak velocity; 
Ts-SD- SD time to peak velocity in 12 segments of LV; Ts-peak (basal)- maximum difference 
in time to peak velocity in 6 basal LV segments. 
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There were limitations in the methods used to analyse the data in this trial.   The 
investigators used 3 core laboratories with limited standardisation of protocols 
especially for the analysis of TDI data.  Re-evaluation of data in the core lab also 
identified that 20% of patients had an EF >40% (107).  In addition, PROSPECT only 
analysed 12 markers of dyssynchrony and excluded techniques such as speckle tracking 
and more complex 3D models of mechanical dyssynchrony.  The time to peak 
transverse and longitudinal strain predicted a response to BiV pacing in the MADIT-
CRT trial but these measurements were not analysed in the PROSPECT trial (61, 95).   
  Therefore, in spite of the non-responder rate, QRS duration remains the gold 
standard for selecting patients for permanent BiV pacing, in the absence of a reliable 
echocardiographic marker of dyssynchrony, from randomised-control trials.  This 
conclusion has been reinforced by the findings of the recently published ‘CRT in heart 
failure with a narrow QRS complex’ (ECHO-CRT) trial. 
The ‘CRT in heart failure with a narrow QRS complex’ (ECHO-CRT) 
investigators reported that BiV pacing (CRT-D) did not reduce mortality or heart failure 
hospitalisation compared to a control group (ICD-only) with NHYA 3-4 heart failure, 
QRS <130 ms, EF <35% and mechanical dyssynchrony (108).  Dyssynchrony was 
defined as either an 80 ms delay in opposing-wall time to peak systolic velocity using 
TDI in the apical 4-chamber or 2-chamber views or 130 ms delay using speckle tracking 
with radial strain in the mid-parasternal short axis between the septum and posterior 
wall.  The study was stopped on the grounds of futility, after enrolling 809 patients with 
an average of 19 months follow-up.  BiV pacing group had a higher death rate 
compared to the control group (11.1% v 6.4%; HR 1.81, 95% CI: 1.11-2.93; p=0.02) 
and more inappropriate ICD discharges, 20 (5%) v 7 (1.7%), p=0.01.   
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1.2.7 Peri-operative tissue Doppler imaging 
Peri-operative TDI has also been investigated as a method of predicting regional 
recovery after coronary artery bypass surgery (109).  Experimental models have shown 
a close relationship between tissue Doppler velocities and sub-endocardial blood flow 
(110, 111).   
TDI measurements were taken using TTE before induction of anaesthesia and at 
6-weeks post-discharge and using TOE after induction and sternotomy but before going 
into bypass and 4-hours post surgery, while ventilated.  Acute changes in peri-operative 
TDI were highly variable and did not predict functional recovery at 6-weeks after 
discharge.  
 
1.2.8 Summary 
There are limitations in using both electrical and mechanical markers of 
dyssynchrony to predict a response to BiV pacing.  QRS duration and morphology are 
currently used to select patients for permanent BiV pacing but about 1/3 patients fail to 
respond to cardiac resynchronisation.  Mechanical dyssynchrony is more prevalent in 
heart failure patients than controls but the clinical utility and reproducibility of these 
measurements limits their clinical application. 
Dyssynchrony may develop de novo after cardiac surgery due to IR injury.  
Invasive ventilation/sternotomy, inotropes, increased loading conditions, ischaemia-
reperfusion injury and RV-only pacing are potential explanations.  Therefore, in patients 
with severe LV dysfunction, temporary BiV pacing may be beneficial after on-pump 
surgery irrespective of baseline QRS duration.     
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1.3 Acute haemodynamic response to biventricular pacing 
Biventricular pacing is achieved by attaching pacing wires to the right atrium, 
right ventricle and left ventricle.  To stimulate the left ventricle, wires are either 
deployed via the coronary venous network or attached to the epicardial surface of the 
heart.  Biventricular pacing has several mechanisms of optimising cardiac function 
leading to an acute augmentation of stroke volume and LV filling: 
 Systolic resynchronisation: correcting LV lateral wall delayed contraction. 
 Increasing LV filling time, reducing LV filling pressures and optimising the AV 
interval. 
 Relief of pericardial constraint/minimising diastolic ventricular interaction 
 Reducing secondary and pre-systolic mitral regurgitation. 
Pacing studies have been performed to investigate the relationship between 
haemodynamic status and pacing mode, see table 4.  Most studies have compared either 
intrinsic rhythm or atrial-inhibited pacing (AAI) to atrial synchronous right ventricular 
pacing (DDD-RV); atrial synchronous BiV pacing (DDD-BIV) and atrial synchronous 
left ventricular pacing (DDD-LV).   The studies listed in table 4 are in patients who had 
been prescribed optimal medical therapy for heart failure.  The ‘relative effect’ is the 
relative change in haemodynamic parameter compared to intrinsic rhythm/AAI pacing 
unless otherwise stated.   
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Table 4: Acute haemodynamic effect of BiV pacing in heart failure patients–NYHA 3-4. 
 
 Yu et al compared BiV pacing to RV pacing and no pacing in 33 heart failure 
patients with severe LV dysfunction (EF 24.2±12.4%) and intra-ventricular 
Investigator n PR QRS EF Haemodynamic 
parameter 
Relative 
Effect 
p 
Yu (62) 33 217±53 158±22 24±12 EF ↑25% 0.02 
Butter (112) 30 194±26 152±77 23±8 dP/dTmax ↑12% <0.01 
Blanc (113) 27 NA 171±31 27±6 Systolic BP † ↑6% <0.01 
Auricchio (114) 27 211±37 168±29 21±6 +dP/dTmax † ↑13% <0.01 
Breithardt 
(115) 
24 181±41 176±25 21±6 EF 
dP/dTmax 
↑24% 
↑37% 
<0.01 
<0.001 
Leclerq (116) 18 221±52 170±37 19±5 CI ↑35% <0.001 
Kass (117) 18 204±69 157±36 19±7 dP/dTmax ↑13% 0.001 
Breithardt 
(118) 
16 211±38 176±4 21±6 +dP/dTmax † ↑18% 0.001 
Key: 
† Haemodynamic comparison of DDD-BiV pacing v DDD-RV pacing. 
All other comparisons are between AAI pacing or sinus rhythm and BiV pacing. 
NA- Information not available/ result not reported in the published manuscripts.  
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dyssynchrony (QRS 158±22ms) (62).  Biplane ejection fraction, non-invasive 
+dP/dTmax and tissue Doppler characteristics were measured using TTE, 2 days after 
device implantation.  Each pacing mode was programmed for 30 minutes before 
haemodynamic evaluation.  BiV pacing improved EF and +dP/dTmax compared to RV 
pacing and no pacing (EF 30±14% v 25±10% v 24±10%; p=0.02) and (+dP/dTmax 
795±239 mm Hg/s v 686±227 mm Hg/s v 577±214 mm Hg/s; p=0.04) respectively.  
BiV pacing also reduced the percentage area of mitral regurgitation (24.0±20.4% v 
35.3±25.9% v 34.5±24.6%; p=0.02).  A 12-segment model of the LV (6-basal and 6-
mid segments) was constructed and the time to peak systolic velocity was measured 
using TDI.  BiV pacing reduced the SD of time to peak velocity of the 12-segments 
compared to RV and no pacing (32.8±13.5ms v 40.2±14.8 ms v 39.6±13.3 ms; p=0.04).        
 Blanc et al studied the acute haemodynamic effects of BiV and LV pacing 
compared to RV pacing (113).  23 patients with EF <35% and mean QRS 171±31ms 
were included in this study.  Transvenous pacing catheters were inserted into the RA 
appendage, RV apex and then moved to RVOT.  The lateral wall of the LV was paced 
using a retrograde catheter inserted via the aortic valve.  Cardiac index was measured 
using thermodilution PA catheters and blood pressure via a femoral arterial line.  Pacing 
the RVOT did not improve SBP compared to RV apical pacing (116.6 mm Hg v 121.4 
mm Hg; p=NS).  LV and BiV pacing increased SBP and reduced capillary wedge 
pressure compared to RV pacing (SBP: 123.3±13.9 mm Hg v 122.1±13.6 mm Hg v 
114.9±15.4 mm Hg; p <0.001) and (PCWP: 19.6±5.1 mm Hg v 20.7±5.6 mm Hg v 
25.5±5.8 mm Hg; p<0.001) respectively.   
 Auricchio et al measured invasive +dP/dTmax and intra-aortic pulse-pressure in 
22 heart failure patients with QRS >120ms, during implantation of a permanent BiV 
pacemaker under general anaesthesia (114).  Haemodynamic measurements were taken 
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during 5 paced beats followed by 15 non-paced beats in VDD mode with RV, BiV and 
LV stimulation.  All measurements were repeated 5 times.  BiV and LV pacing 
increased LV +dP/dTmax by 14.4% and 15.3% compared to RV pacing (p <0.05).  The 
optimal AV interval producing the maximum LV +dP/dTmax was 110±14 ms and 98±52 
ms for LV and BiV pacing producing a 23% and 22% increase in SBP compared to 
nominal settings (PR interval-30 ms).      
Therefore, acute BiV pacing augments cardiac output in heart failure patients 
who are prescribed optimal medical therapy, with severe LV systolic dysfunction and 
intra-ventricular conduction delay.  BiV pacing increased ejection fraction by an 
absolute value of 5-6% (62, 115)  and cardiac index 0.7 L/min/m
2  
(116) compared to 
intrinsic rhythm
  
(p <0.01 and p=0.02 respectively).   
 
1.4 Biventricular pacing after cardiac surgery 
The studies in table 4 have shown a clear pattern than reversing dyssynchrony 
with BiV pacing produces an acute augmentation in cardiac function.   
The next question is whether biventricular pacing can produce similar results 
and improve LV function after cardiac surgery.  It is important to remember that the 
results in table 4 were produced in patients taking optimal heart failure medications 
including beta blockers and ACE inhibitors.   
Before cardiac surgery, ACE inhibitors are frequently discontinued because of 
the risk of post-operative renal insufficiency and hypotension (14).  Typically, heart 
rates are increased after surgery because of hypovolaemia and the chronotropic effects 
of dobutamine, PDE III inhibitors (milrinone/enoximone) or adrenaline.   
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After surgery, positive pressure ventilation and ischaemia-reperfusion injury 
may impede the potentially beneficial effects of BiV pacing (44).  Positive pressure 
ventilation increases intra-thoracic pressure and right atrial pressure and reduces 
systemic venous return/RV pre-load and cardiac output (119-121).   RV after-load 
remains relatively unchanged unless PEEP exceeds 10 mm H20.  Patients with 
asthma/COPD experience a rapid increase in PVR with ventilation due to collapse of 
extra-alveolar vessels and/or hypoxia with a significant rise in RV after-load (122).  
However, PEEP reduces LV after-load and can be beneficial in treating acute 
pulmonary oedema. 
Around 9% of patients develop post-operative AV block and require temporary 
ventricular pacing (123).   This is usually achieved by pacing the right ventricular free 
wall, which induces intra-ventricular dyssynchrony, which is equivalent to LBBB (123-
127).  In addition, inotropic ‘stress’ may prolong the QRS duration by up to 8 ms and 
prolong the isovolumic period (p <0.001) (128).  Therefore, patients with severe LV 
dysfunction may benefit from LV pacing wires to protect against RV-only pacing after 
surgery. 
 
1.5 Temporary biventricular pacing after cardiac surgery 
Despite the adverse effects of right ventricular pacing and the detrimental effects 
of cardiac surgery on mechanical dyssynchrony, studies of the beneficial effects of 
acute biventricular pacing in the post-operative setting have been inconclusive, see table 
5.  This table illustrates the relative effect of BiV pacing compared to AAI pacing or 
intrinsic rhythm unless otherwise stated. 
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Table 5: Results of acute biventricular pacing after cardiac surgery. 
Investigator n QRS EF Endpoint Effect p 
Straka (129) 
2011 
18 >120 24±4 Cardiac output 
Cardiac index 
↑22% 
↑21% 
<0.001 
<0.001 
Eberhardt 
(130) 
2009 
94 110±16 35±4 Cardiac index 
NT-PRO-BNP 
SV02 
MAP 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
Hanke (131) 
2009 
21 98±17 29±6 Cardiac index† 
dP/dTmax 
↑11% 
↑18% 
<0.05 
<0.01 
Evonich (132) 
2008 
40 111±30 23±6 Cardiac index 
MAP 
NS 
NS 
0.83 
0.52 
Muehlschlegel 
(133) 2008 
10 117±37 35±6 Cardiac 
output† 
↑4%  0.3 
Schmidt (134) 
2007 
26 132±25 27±7 Cardiac index 
PAP 
PCWP 
NS 
NS 
NS 
NS 
NS 
NS 
Flynn (135) 
2005 
25 <120 33±10 Cardiac index* 
LVSWI 
MAP 
↑12% 
↑15% 
↑5% 
<0.02 
<0.01 
<0.01 
Saxon (136)   
1998  
11 139±39 <35% FAC (TOE) ↑21% <0.01 
Foster (137) 
1995 
18 NA >40%  Cardiac Index ↑8% <0.05 
Key: 
*= comparison of atrial-LV posterior wall pacing to dual chamber RV pacing. 
†= comparison of BiV pacing to dual chamber RV pacing. 
NS= p value non-significant, exact value not published. 
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Eberhardt et al (130) performed the largest haemodynamic study of temporary 
post-operative BiV pacing (n=96).  This trial included patients undergoing CABG with 
an EF <40% and pacing was continued for 96 hours after surgery.  94% had narrow 
QRS durations <120ms, mean duration 100±16 ms and 6% had a bundle-branch block.  
Patients were excluded if they developed post-operative atrial fibrillation and did not 
cardiovert with amiodarone or electrical defibrillation.   
Patients were randomly assigned to either post-operative BiV pacing, DDD-
RVOT pacing or AAI pacing.  Pacing was initiated prior to separation from cardio-
pulmonary bypass circuit, at a rate of 90 beats per minute for 96 hours with an AV 
interval 120ms for BiV pacing and 150 ms for DDD-RVOT pacing.  Cardiac index was 
measured using a PA catheter.  The index was the average of 3 thermodilution 
measurements.  
BiV pacing did not improve haemodynamic function (cardiac index or LV 
cardiac power index) or reduce the median duration of ITU admission compared to AAI 
or atrial synchronous-RVOT pacing: (ITU duration: 20 hours v 19 hours v 21 hours 
respectively; p=NS).  The frequencies of post-operative arrhythmias, renal failure and 
IABP insertion were not influenced by pacing mode.  Post-operative NT-pro-BNP, TnT 
and mixed venous oxygen saturations were similar in all 3 groups.  3 patients in the BiV 
group required post-operative IABP and 1 patient in the AAI group and 2 patients in the 
BiV group and 1 patient in the DDD-RVOT group required post-operative 
haemofiltration.   
At 30-days, 1 patient in each group had died (n=3) and 1 patient in the DDD-
RVOT group had a stroke. This trial concluded that BiV pacing was feasible after 
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cardiac surgery but there was no clear advantage with BiV pacing compared to AAI or 
atrial synchronous-RVOT pacing.      
Although Eberhardt reported that BiV pacing was similar to atrial inhibited and 
RV pacing, an initial study by Hanke et al reported improved haemodynamic function 
with BiV pacing compared to RV pacing in the operating theatre (131).  Hanke et al, 
studied the haemodynamic effect of temporary BiV pacing (n=21) in patients with 
narrow QRS and EF <35%.  Haemodynamic function was measured using pressure-
volume (PV) loop analysis, 15-30 minutes after separation from the cardio-pulmonary 
bypass circuit.  PV loops were recorded 30 seconds after changing pacing mode.  
Haemodynamic data were collected during AAI pacing and dual chamber BiV and LV 
pacing compared to RV outflow tract pacing.   
BiV pacing improved cardiac index by 0.22 L/min/m
2
 compared to RV pacing.  
All pacing modes improved +dP/dTmax and - dP/dTmax, end-systolic elastance and 
ventriculo-arterial coupling compared to RV pacing- (991±263 mm Hg/s v 841±236 
mm Hg/s; 0.87±0.24 mm Hg/ml v 0.79±0.22 mm Hg/ml; 0.775±0.667 v  0.682± 0.232 
BiV v RV pacing respectively; p<0.05).  This study only measured cardiac parameters 
for a brief period of time while the sternum was open.  However, it suggests that BiV or 
LV pacing is superior to RVOT pacing in patients with post-operative AV block.   
However, there was no advantage to BiV/LV pacing compared to AAI pacing in 
patients with intact AV conduction. 
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Straka et al studied the effect of BiV pacing compared to LV and RV pacing 
within 72 hours of bypass surgery in 21 patients with severe LV dysfunction EF <35% 
and either QRS >150ms or >120 ms with mechanical dyssynchrony on 3D TOE  (129).  
Mechanical dyssynchrony was assessed using the systolic dyssynchrony index.  This 
index is the standard deviation of the time to minimum LV systolic volume in all of the 
16 segments of the LV.  The index is expressed as a percentage of the RR interval to 
eliminate the effects heart rate variability.  The site of LV pacing was also defined by 
the site of latest activation using a bull’s-eye map of LV segment activation before 
surgery.  The RV leads were attached adjacent to the septum in the lower third of the 
anterior wall.  The AV and VV intervals were also optimised using the velocity time 
integral (VTI) of mitral inflow and LV outflow tract VTI respectively.    
Haemodynamic measurements were taken on arrival to the ITU and at 24, 48 
and 72 hours after surgery using thermodilution catheters.  11 patients had valve surgery 
but the cardio-pulmonary bypass time was similar to Eberhardt’s study (130): 113±34 
mins v 105±39 mins, respectively.  The sites of latest LV activation were mid-
anterolateral (33%), basal-anterolateral (19%) and basal inferolateral (19%) segments.  
The optimal AV interval was 152±19 ms, and 11/20 patients benefited from LV pre-
activation.   
BiV pacing and LV pacing were superior to RV pacing: they increased MAP 
(77±10 mm Hg v 78±9 mm Hg v 73 mm Hg; p=0.03); cardiac output (6.7±1.7 L/min v 
6.2±1.5 L/min v 5.4±1.4 L/min; p=0.01) and LV stroke work index g.m/m
2
 (8.6±2.7 v 
8.1±3 v 7±2.4; p=0.0025).  There was no difference in pulmonary vascular resistance 
between pacing modes.  The durations of inotropic support and ITU admission were 
shorter in the BiV and LV paced groups compared to RV pacing: inotropic duration 
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/days (2.8±2.3 v 1.9±1.5 v 5.1±2.6 days; p <0.05) and ITU duration /days (3.1±1.9 v 
2.6±1.2 v 4.1±2.1) respectively.      
Evonich et al (132) enrolled 40 patients with severe LV dysfunction and narrow 
QRS duration into 3 treatment groups after cardiac surgery: ‘usual care’, atrial-right 
ventricular and atrial-BiV pacing.  The primary endpoint was the duration of ITU 
admission and secondary endpoints included haemodynamic studies using a PA 
catheter.   29/40 patients completed the haemodynamic studies at 12 hours.  This study 
included patients with IABP (n=11) and valve surgery (n=16).  There was no overall 
difference in cardiac output, stroke volume or mean arterial pressure between atrial only 
and BiV pacing.  A trend was observed that BiV pacing may be beneficial in patients 
with lower ejection fractions compared to atrial-only pacing.  However, atrial-only 
pacing was superior to atrial-right ventricular pacing.    
The duration of ITU admission was not influenced by pacing mode.  There was 
a high cross-over of patients from their assigned pacing mode (n=10) and the primary 
endpoint was analysed using both intention to treat and on-treatment analyses.  This 
study suggested that if patients require ventricular pacing because of AV block, BiV 
pacing would appear preferable to right ventricular only pacing. 
Flynn et al (135) studied the acute haemodynamic effects of BiV pacing using 
similar pacing modes to Foster et al (137).  The patients enrolled by Flynn had a lower 
ejection fraction and narrow QRS durations.  This study of 25 patients also compared 
LV pacing in 2 separate sites, the anterior and posterior walls of the LV.  Both LV sites 
improved LV stroke work index compared to RV pacing.  However, only posterior wall 
LV pacing improved cardiac index by 12% compared to RV pacing.    
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Foster et al (137) studied the acute haemodynamic effects of pacing mode on 
cardiac index using thermodilution catheters 12-36 hours after cardiac surgery.  Pacing 
leads were attached to the right atrium, and the para-septal regions of the right and left 
ventricle.  Haemodynamic studies were performed after 10 minutes of over-drive pacing 
using AV sequential pacing and stimulation of the right ventricle, left ventricle and both 
ventricles simultaneously.  Most patients (14/18) had an ejection fraction greater than 
40%.  BiV pacing produced a significant 8% improvement in cardiac index compared to 
the other pacing modes (p<0.05) but no overall change in mean arterial pressure or 
pulmonary diastolic pressures. 
In summary, the largest study of post-operative BiV pacing reported that BiV 
pacing was similar to RV pacing (130).  The results may have been influenced by the 
site of RV pacing (RVOT rather than RV apex), the exclusion of AV/VV optimisation 
protocols, and LV pacing at a fixed location rather than the site of latest LV activation.   
The study by Straka et al (129) addressed these issues and also enrolled patients 
with pre-operative dyssynchrony defined as QRS >120ms. The investigators reported 
that BiV pacing improved cardiac index by 24% and reduced the duration of inotropic 
support by 2.3 days.  Therefore, selecting patients with either baseline dyssynchrony or 
including optimisation protocols may be required for patients to benefit from BiV 
pacing after cardiac surgery. 
 
1.5.1 Permanent biventricular pacing after cardiac surgery 
Pokushalov et al conducted the largest trial of post-operative BiV pacing.  178 
patients received a permanent epicardial CRT pacemaker after surgical revascularisation 
and half received BiV pacing (CRT ‘on’) and the other half did not (CRT ‘off’).  All 
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patients had a diagnosis of heart failure with severe LV systolic dysfunction (EF ≤35%) 
and baseline dyssynchrony (138).  Baseline dyssynchrony included: QRS duration >120 
ms; aortic pre-ejection delay >140 ms; inter-ventricular mechanical delay >40 ms or 
intra-ventricular dyssynchrony using tissue tracking or tissue Doppler imaging.    
The primary endpoint of total mortality at 18 months and duration of ITU stay 
was lower in the BiV pacing group compared to the control arm of the study (10% v 
26.1%; p=0.006 and 2.5±0.5 days v 3.9±0.6 days respectively).  Remodelling and 
reversal of dyssynchrony was only observed in the CRT ‘on’ group with a 12% increase 
in EF compared to baseline (p<0.001).   Heart failure hospitalisation was reduced in the 
CRT arm of the study (6.6% v 21.9%) and NYHA class (2.2±0.7 v 3.5±0.3, p<0.001) 
compared to CABG-only.  Dyssynchrony was identified as an independent marker of 
all-cause mortality and heart failure hospitalisation.  
However, this study did not measure acute haemodynamic function after cardiac 
surgery.  It would have been interesting to see if the reversal of dyssynchrony with BiV 
pacing improved acute haemodynamic function.  In addition, the study protocol did not 
address the issue of protecting patients from sudden arrhythmic cardiac death.  The 
patients were not assessed after revascularisation for an implantable defibrillator in 
either treatment group.  Finally, the investigators did not report any improvement in LV 
ejection fraction with CABG-only.  Although myocardial viability was not formally 
assessed, revascularisation of viable/hibernating myocardium should yield an 
improvement in ejection fraction (4). 
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1.5.2 Left ventricular size 
 Dzemali et al (139) studied the effect of temporary BiV pacing in 80 patients 
after cardiac surgery with pre-operative EF <35%.  Patients were divided into 2 cohorts 
depending on LV size: dilated (mean LVEDD 65±5mm) and normal/mildly dilated LV 
(mean LVEDD 52±4mm).  Cardiac index and blood pressure were measured at 
baseline, 6 hours and 24 hours after the operation.  67.5% (n=27/40) in the dilated LV 
group and 55% (n=22/40) in the normal size LV group showed a haemodynamic 
response to BiV pacing.   
In patients with dilated LV, BiV pacing reduced the duration of ventilation and 
intensive care admission compared to atrial synchronous right ventricular pacing and 
baseline QRS duration did not predict a haemodynamic response to BiV pacing.   
Therefore, patients with dilated LV respond better to BiV pacing after cardiac surgery 
compared to patients with normal sized LV but both groups had responders to BiV 
pacing.   Acute BiV pacing did not augment cardiac index in around 1/3 patients with 
dilated LV. 
 
1.5.3 Left ventricular pacing site 
 The previous haemodynamic studies of BiV pacing (see table 4 and 5) have 
implanted the LV leads in different locations, including: para-septal, anterior and 
posterior walls.  Flynn et al (135) demonstrated that posterior but not anterior LV 
pacing during BiV stimulation improved cardiac index compared to RV pacing.    
The investigators of the large randomised trials of BiV pacing have performed 
post-hoc analyses of outcome determined by the site of LV pacing.  The data from 
MADIT-CRT (n=799) were analysed in reference to LV lead position and the primary 
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outcome of heart failure hospitalisation or death (89).  The primary endpoint of heart 
failure hospitalisation or death and the secondary endpoint of total mortality were 
increased with apical v non-apical pacing (HR 1.72; 95% CI 1.09-2.71, p=0.019 and HR 
2.91; 95% CI 1.42-5.97, p= 0.04 respectively).  Pacing the anterior, lateral or posterior 
LV wall did not affect these outcome measures.   The COMPANION trial (n=1520) 
found that a lateral LV lead positioning produced the best acute haemodynamic 
response to BiV pacing but all lead positions improved functional class, 6 minute walk 
distance and quality of life score (90).  Therefore, non-apical pacing appears better than 
apical pacing (89) and the data also suggest that a lateral lead position is best although 
this is less robust (90).  An advantage of attaching temporary wires to the heart after 
cardiac surgery is that lead position is not limited by the venous anatomy of the heart 
which is a constraint with transvenous pacing. 
There are data to support post-operative pacing at the site of latest LV activation 
(129).  This technique has been used when implanting permanent BiV devices to 
achieve optimal invasive +dP/dTmax which may also predict LV remodelling (91).   
However, it is possible that the site of latest activation may alter after cardio-pulmonary 
bypass.  In addition, the temporary leads are attached during weaning from the bypass 
circuit, when the heart is under-filled and hypo-contractile after cardioplegia.  This 
makes this technique technically more difficult. 
The trial by Straka et al (also discussed in section 1.5) investigated the acute 
haemodynamic effect of BiV pacing after cardiac surgery in 21 patients with QRS 
>150ms or QRS >120ms with mechanical dyssynchrony and EF <35% (129).  3D TOE 
tissue Doppler was used to identify the site of latest LV activation before surgery and 
the AV/VV intervals were optimised.   
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The mid-anterolateral segment of the LV was the most frequent site of latest 
activation, in 33%, but the optimal site was highly variable.  BiV pacing also increased 
cardiac index by 25% (p<0.001) compared to RV pacing.  However, the incremental 
benefits of AV/VV optimisation and optimal compared to nominal LV pacing sites were 
not reported.   
Implanting the LV lead at the site of latest LV activation has also been 
investigated in patients receiving permanent BiV pacemakers (140).   In the TARGET 
trial, 220 patients with conventional indications for BiV pacing had an echocardiogram.  
Using speckle tracking, radial strain was used to identify the region of latest LV 
activation and avoid pacing within scar tissue.  Targeted LV pacing was compared to 
unguided lead implantation.  The primary endpoint was a ≥15% reduction in LV end-
systolic volume at 6-months. There was an absolute increase of 15% (70% v 55%) in 
LV remodelling with targeted lead implantation compared to unguided implantation 
(95% CI: 2-28%; p=0.031).  The posterior or lateral walls were the latest site of LV 
activation in 70% of patients. 
In a similar study, Delgado et al reported in 397 patients, that concordant LV 
pacing reduced mortality compared to discordant pacing at 3-year follow up (80% v 
54%; log-rank p <0.001) (141).  LV leads placed within a region of scar tissue (>50% 
LV wall thickness, identified by peak radial strain <16.5%) reduced survival by 29% at 
3-years, compared to no scar tissue (58% v 87%; log-rank p <0.001) (figure 7). 
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Figure 7: Time to peak radial strain using speckle tracking. 
 
Assessment of segmental peak radial strain by 2-dimensional speckle tracking imaging. From 
the time–radial strain curves, peak radial strain can be quantified for each segment in which the 
left ventricle is divided. A pre-established cutoff value of 16.5% defines the presence of 
transmural myocardial scar-A, An example of a patient with myocardial scar in the latest 
activated segments (lateral and posterior segments; peak radial strain <16.5%; arrows). B, In 
contrast, an example of a patient without myocardial scar in the latest activated segments (peak 
radial strain >16.5%; arrows). 
Adapted from Delgado et al (141). 
 
Therefore, pacing outside of scar tissue and at the site of latest activation is 
associated with improved LV remodelling and survival compared to standard unguided 
techniques.  After cardiac surgery, transmural infarction may be identified by inspecting 
the heart, before implanting the temporary epicardial wires to avoid pacing over scar 
tissue.  Likewise, imaging techniques can be utilised to guide LV lead position, at the 
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site of latest LV activation.  If this is not feasible, then the posterior or lateral LV walls 
are the favoured locations for LV pacing. 
 
1.6 Optimisation of timing cycles (AV and VV intervals) 
 The studies of haemodynamic response to BiV pacing listed in table 4 and 5, 
with the exception of the study by Straka et al (129), have used nominal AV intervals 
and simultaneous RV and LV activation.  However, the haemodynamic response to BiV 
pacing may be enhanced by optimising the AV/ VV pacing intervals. 
 
1.6.1 Atrio-ventricular interval (AV) optimisation 
 Optimisation of the AV interval can augment LV filling and subsequent stroke 
volume (figure 6).  However, it appears that the optimal AV interval varies for each 
individual patient hence the variation optimal AV delays reported in table 6.   
There are several methods of optimising the AV interval including: 
echocardiography; PA catheters (cardiac output/index); pressure-volume loops; invasive 
dP/dTmax; mean arterial blood pressure monitoring; finger plethysmography and 
impedance cardiography.   
In clinical practice, optimisation of permanent BiV devices is usually performed 
using echocardiography due to its availability and non-invasive technique.  Methods of 
optimisation include: measuring the VTI of the pulsed mitral inflow; direct visualisation 
of the E and A filling pattern, the ‘iterative method’ and measuring the VTI of the LV 
outflow tract (stroke distance) (142).  Previous studies have reported significant 
improvements in haemodynamic function with optimisation of pacing intervals assessed 
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using serial measurements of invasive dP/dTmax, blood pressure and cardiac output 
(table 6).  
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Table 6: Beneficial effects of AV interval optimisation on haemodynamic function. 
Trial n Opt Method Effect of Opt Timing 
of Opt 
Optimal AV 
delay (ms) 
VV 
opt 
PATH-CHF 
(77) 
41 Invasive LV 
dP/dTmax 
↑17% Implant 112±33 No 
Auricchio (114) 27 Invasive LV 
dP/dTmax 
↑22% Implant 98±52 Yes 
Van Gelder 
(143) 
34 Invasive LV 
dP/dTmax 
↑10% Implant 147±32 Yes 
Heinroth (144) 46 Impedance ↑11% CO 3-5 days 119 Yes 
Butter (145) 57 FPPG ↑16.1 Invasive 
APP 
Implant  No 
Whinnett (146) 15 FPPG ↑21 mm Hg 
systolic BP 
3-30 
months 
168 Yes 
Meluzin (147) 18  Echo: mitral 
inflow 
↑0.2 L/min CO 
by Swan Ganz 
3 months 148±17 No 
Riedlbauchova 
(148) 
19  Echo: LVOT 
CO 
↑0.6 L/min 
LVOT CO 
 140 Yes 
Vidal (149) 100 Echo: Iterative 
MV inflow 
↑0.7 L/min CO 
by aortic valve 
VTI 
24-72 
hours 
137 Yes 
Key: 
APP- aortic pulse pressure 
FPPG- Finger plethysmography. 
Opt- Optimisation. 
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Auricchio et al reported a 22% increase in +dP/dTmax by optimising the AV 
interval in 27 patients in sinus rhythm with moderate to severe heart failure and 
prolonged AV delay (PR interval ≥150ms) and intra-ventricular delay (QRS ≥150 ms) 
(114).   There was substantial variation in the optimal AV interval, which measured 98 
±52 ms.  Therefore, every patient required a haemodynamic study to define their 
optimal pacing intervals. 
Likewise, the ‘Pacing Therapies in Chronic Heart Failure’ (PATH-CHF) trial 
investigated the acute haemodynamic response to AV optimised pacing and the long 
term benefit of resynchronisation, in subjects with heart failure and intra-ventricular 
delay (77).  Optimisation of the AV delay at implantation augmented invasive 
+dP/dTmax (+17 ±15.8%; p <0.001) compared to intrinsic PR interval.  The optimal AV 
interval was shorter than the intrinsic PR interval (112 ±15.8 ms v 190 ±34 ms, 
respectively).  After 1 year, BiV pacing produced significant improvements in oxygen 
uptake during exercise, and in a 6 minute walk test (p <0.05).   
Prospective randomised control trials of cardiac resynchronisation have included 
AV optimisation protocols.  The COMPANION trial (150)  used a device-based 
algorithm and the MUSTIC (75), MIRACLE (78) and CARE-HF (60) trials used pulsed 
mitral inflow patterns on transthoracic echocardiography to predict the optimal AV 
delay.  However, there is a limitation to these trials in that the clinical benefit of AV 
optimisation could not be quantified in the absence of a BiV pacing control group with 
nominal pacemaker settings.  
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1.6.2 Inter-ventricular interval (VV) optimisation   
The presence of LV scar is a potential explanation for the failure to demonstrate 
a response to BiV pacing.  Scar tissue may delay the propagation of LV depolarisation 
and hence lead to ineffective cardiac resynchronisation.  Therefore, optimal LV lead 
placement should avoid scar tissue and target the region of latest LV activation.   
LV lead placement is more of a problem with transvenous pacing.  The options 
for LV pacing are limited by suitable conduits to accommodate a pacing wire but 
epicardial pacing is not restricted by the venous anatomy of the heart.  Epicardial pacing 
wires can be placed away from transmural scar, but subendocardial scar may be difficult 
to visualise from the epicardial surface of the heart.      
LV pre-activation may be a potential solution to sub-optimal LV lead placement 
and optimise response rates to BiV pacing.  Pre-activation of the LV (or RV) may 
compensate for areas of slow conduction.  The clinical benefit of VV optimisation is 
illustrated in table 7. 
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Table 7: Effects of VV optimisation of parameters of LV function. 
Trial n Optimisation 
Method 
Timing of 
Optimisation 
Effect of 
Optimisation 
Rao (151) 306 Device algorithm 2 weeks None 
Leon (152) 
(Insynch III) 
359 Echo LVOT VTI Pre-discharge ↑7.3% stroke volume 
↑15.1m 6MWT 
Boriani (153) 121 Echo LVOT VTI  None 
Bordachar 
(154) 
41 Echo LVOT VTI Implant ↑0.8 L/m CO 
Sogaard (155) 20 Tissue Doppler 24 hours ↑3.9% LVEF 
↑7% DFT 
Vidal (149) 100 Tissue Doppler 24-72 hours ↑0.7 L/min CO  
Van Gelder 
(156) 
53 Invasive dP/dTmax <24 hours ↑8% dP/dTmax 
 
 These studies have used echocardiography, invasive +dP/dTmax and CRT device 
algorithms to optimise the VV interval.  The study by Rao et al (151) was designed to 
show equivalence of simultaneous BiV pacing, sequential BiV pacing and LV pacing.  
The sequential pacing group were VV optimised using a device based algorithm (CRT 
device- CONTAK RENEWAL, Boston Scientific).  The device recorded intra-cardiac 
electrograms during device implant to predict the optimal VV interval.  A similar 
algorithm was used to calculate the optimal AV interval for all patients.  This aimed to 
maximise the percentage of BiV pacing.  
54 
 
An improvement in stroke volume and ejection fraction was observed in all 
groups compared to baseline. There was no additional advantage of VV optimisation 
compared to simultaneous BiV pacing with respect to LV remodelling, stroke volumes 
or indices of diastolic function.  
However, echocardiogram guided optimisation using LV outflow tract VTI has 
been reported to improve stroke volume, 6 minute walk distance and cardiac output 
(152, 154).  Leon et al (152) measured the change in stroke volume with VV 
optimisation  compared to simultaneous pacing in 422 patients with NHYA III/IV, EF 
<35%, QRS >130ms, LVEDD >55mm.  At 6 months, 88% of patients benefitted from 
VV interval optimisation, but only 7.3% achieved a >20% in stroke volume, compared 
to simultaneous VV pacing. 
Boriani et al (153) compared simultaneous (n=31) to sequential (n=90) BiV 
pacing in heart failure patients with severe LV systolic impairment.  Both treatment 
arms improved heart failure symptoms and 6 minute walk test but there were no 
differences between the 2 groups at 6 months.   
Sogaard et al (155) studied the effects of VV optimisation in 20 patients with 
NHYA 3-4 symptoms, QRS >130ms, EF <35%.  Post device implant echocardiography 
revealed a 7.3% increase in EF with BiV pacing compared to no pacing and a further 
3.9% increase in EF and a 9% reduction in LV end-systolic volume with VV 
optimisation (p <0.05).  
Vidal et al (149) compared BiV pacing with a nominal AV interval of 120 ms 
and sequential BiV pacing to echocardiogram-guided AV and VV optimised patients 
with EF <35% and QRS >120ms.  At 6 months, optimisation improved 6 minute walk 
distance by 104 m (p <0.01) and cardiac output (4.3±1.4 L/min v 3.6±0.5 L/min; 
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p<0.05) compared to nominal settings but heart failure symptoms were similar in both 
groups.  This study optimised both AV and VV intervals and did not report separate 
results on the incremental benefit of VV optimisation.   However, Van Gelder et al 
(156) reported a significant improvement in invasive +dP/dTmax with VV optimisation, 
in 53 heart failure patients, NHYA 3-4 patients, QRS >150 ms and EF <35%.  VV 
optimisation increased +dP/dTmax by 8% and LV pre-activation increased +dP/dTmax in 
73% of patients.   
 
1.6.3 AV/VV interval optimisation of BiV pacing after cardiac surgery 
The data in table 6 and 7 support the argument that the AV and VV intervals 
should be optimised in patients receiving BiV pacing.  However, at the start of this 
research project in 2009, there were limited data on the clinical utility of optimising 
temporary BiV pacing after cardiac surgery.   
Wang et al studied the effect of AV and VV optimisation in 20 patients in sinus 
rhythm with EF 33±15% and QRS 116±19 ms, after separation from the cardiac bypass 
circuit and using a flow probe attached to the aorta (157).  The LV wire was attached to 
the basal segment adjacent to the circumflex artery.  A range of AV intervals from 90 to 
270 ms using 30 ms increments, and VV intervals from -80 to +80 ms using 20 ms 
increments, were selected: the negative vector indicated LV pre-activation.   
The optimal AV interval was 171±8 ms and optimisation improved flow by 14% 
compared with the worst setting (111±11 ms; p <0.001) and 7% compared with the 
nominal AV interval (120 ms; p <0.001).  VV optimisation increased flow by 10% 
compared with the worst settings (p <0.001) and 5% compared with nominal settings (p 
<0.001).   Overall, optimised BiV pacing improved flow by 13% compared to atrial-
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only pacing at a matched heart rate (5.5±0.5 v 4.9±0.6 L/min; p=0.003).  These data 
were collected in the operating theatre before closing the chest wall. 
The second phase of this trial was reported by Rubinstein et al in 2012 (158).  
Mean arterial pressure was recorded from 30 patients (this included the 20 patients 
enrolled by Wang et al), after closure of the chest.  Optimising the AV interval 
increased MAP by 7% and 4% compared to the worst and nominal (120ms) AV 
intervals respectively (p <0.001).  Optimisation of the VV interval increased MAP by 
7% and 3% compared to the worst and nominal (VV=0) VV intervals respectively (p 
<0.01).  Optimised temporary BiV pacing failed to augment MAP in approximately 
30% of patients.  
Garcia et al (159) studied the effect of pacing mode on cardiac output using 
thermodilution catheters in 50 patients after on-pump cardiac surgery.  This was a 
heterogeneous population with 2/3 patients having valve replacements and only 1/3 
coronary revascularisation.  The whole spectrum of ejection fractions was studied with 
50% having preserved EF and only 14% EF <35%.  In addition, 16% of patients were in 
AF before surgery.  The LV wires were attached to the posterior wall.  A dual-chamber 
temporary pacemaker was used which allowed AV optimisation for patients in sinus 
rhythm.  For patients in AF, VV optimisation was performed. 
Atrial synchronous LV pacing increased the cardiac output by 7.5% (0.4 L/min) 
in patients with EF <35% compared to baseline measurements. However,  atrial 
synchronous RV pacing decreased cardiac output by 2.3% in all groups of patients 
irrespective of baseline ejection fraction (p<0.05).   
The study did not clearly define the ‘basal’ pacing mode and the heart rate was 
increased by 10% to perform the pacing studies, which would affect cardiac output.  
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Neither did the author report stroke volume, which would help compare the 
haemodynamic effect of pacing to baseline measurements.  Finally, no data were 
presented for AV or VV optimisation, which was described in the methods section.      
Therefore, only 2 studies have presented data on AV and VV optimisation of 
temporary epicardial pacing after cardiac surgery.  Optimisation of pacing intervals 
improved cardiac output and MAP (157, 158) and appears to be beneficial.  The data to 
support optimised BiV pacing after cardiac surgery are limited and further studies are 
required to confirm these findings.   
 
1.7 Haemodynamic monitoring 
Patients with impaired LV function are at increased risk of developing post-
operative SIR syndrome, ischaemia-reperfusion injury and low-output cardiac failure 
(22, 23, 37).  Therefore, monitoring central venous pressure, cardiac output and 
systemic vascular resistance can be helpful, to manage post-operative fluid 
resuscitation, and the requirements for inotropes and vasoconstrictors (160).  
Historically, pulmonary arterial (PA) catheters have been used to measure cardiac 
output.  However, the invasive nature of this device along with its potential 
complications has led to interest in developing less invasive methods of haemodynamic 
monitoring.   
The initial PA catheters were ‘stiff’ and the current design of a catheter with a 
balloon floatation device was only introduced in the 1970s.  Further refinement of the 
catheters allowed measurement of cardiac output using thermodiluation, mixed venous 
oxygen saturations and PA wedge pressure. The principal complications associated with 
PA catheters include: complications from obtaining vascular access including arterial 
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puncture (1.9%); pneumothorax (0.5%); venous thrombosis (2-7%) and air embolus; 
ventricular arrhythmias (<1%); pulmonary infarction; injury to chordae of the tricuspid 
valve (0.9%); bacteraemia (1-2%) and pulmonary artery rupture (0.03%) (161).   
A randomised clinical study of PA catheters compared to a control group 
(without PA catheters) was performed prospectively in over 1,000 patients in 65 critical 
care units in the UK (162).  In a general population of intensive care patients, 
monitoring with a PA catheter failed to reduce in-hospital mortality compared to the 
control group (68% v 66%; HR 1.09; 95% CI 0.94-1.27; p=0.39).  A complication rate 
of 9.5% was associated with using a PA catheter, although no complications were fatal.   
A prospective, observational study of 5735 patients admitted to critical care reported 
that PA catheters were associated with an increased 30-day mortality compared to 
patients who did not receive a PA catheter (OR 1.24; 95% CI 1.03-1.49) (163). 
Alternative methods of measuring cardiac function include: the PiCCO (Pulsion 
Medical Systems, Munich, Germany) and LiDCO (LiDCO, Cambridge, UK) systems 
that analyse the arterial pulse-wave.  However, both systems require invasive calibration 
by trans-pulmonary thermodilution and the PiCCO system also requires central venous 
access.   
The Flotrac/Vigileo system (Edwards Lifescience, Irvine, CA) calculates 
continuous cardiac output from arterial waveform characteristics.  Cardiac output is 
calculated from the pulse contractility and heart rate with corrections for gender, age 
and body surface area.  The algorithms used in this device have been continually 
refined.  At the start of writing this thesis in 2009, version 3 was the most recent 
algorithm.  One of the main limitations of this device is that it cannot analyse the 
arterial pulse-wave in the presence of an intra-aortic balloon pump.   
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Validation studies for the Flotrac device have produced conflicting results.  The 
results of previous validation studies using versions 1.07 and 1.0 of the FloTrac system 
compared to a PA catheter are displayed in table 8.  The methods of agreement 
described by Critchley and Critchley suggests that ‘a percentage error of 30% or less 
between the FloTrac and the PA catheter indicates that the Flotrac is no less accurate 
than the PA catheter (164).   However, 3/6 studies reported a co-efficient above 30%.  
As part of this thesis, a further validation study was conducted between the PA catheter 
and FloTrac/Vigileo system.   
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Table 8:  Validation of the FloTrac/Vigelio system using PA catheters in cardiac patients. 
Author Year Software Setting Reference 
method 
Data 
points 
Bias ± 2 SD or LOA Correlation Percentage 
error 
Button (165) 2007 1.07 OP/ITU TD 150 0.25±2.27 NA 54 
Cannesson (166) 2007 1.07  OP/ITU TD 166 -0.26±1.74 r=0.66 38 
Lorsomradee (167) 2007 1.07 OP CCO 550 Pre CPB: -3%±56% 
Post CPB: -1% ±50% 
r=0.19 NA 
Mehta (168) 2008 1.07 OP TD 96 -0.27±0.44 NA 29 
Staier (169) 2008 1.07 OP TD 120 -0.06±0.91 NA 36 
Chakravarthy (170) 2007 NA OP TD 438 0.15±0.66 r=0.49 NA 
Prasser (171) 2007 1.1 ITU TD 158 0.01±1.63 NA 26.9 
Mayer (172) 2008 1.1 ITU TD 282 0.19±0.63 NA 24.6 
Key: OP=operating room; ITU= intensive care; TD= thermodilution; CCO=continuous cardiac output; CPB=cardiopulmonary bypass; 
LOA=limit of agreement.  Adapted from Mayer et al (173).  
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1.8 Summary  
Coronary artery disease is the leading cause of systolic heart failure.  Patients 
with heart failure may also develop electro-mechanical dyssynchrony, which leads to a 
further decline in stroke volume and LV filling.   
Surgical revascularisation is a therapeutic option for symptomatic heart failure 
subjects with coronary artery disease with ischaemic but viable myocardium.  Pre-
operative LV function is an important determinant of post-operative outcome in patients 
undergoing cardiac surgery.   
BiV pacing improves haemodynamic function in non-surgical patients with 
prolonged QRS durations >120ms by reversing electro-mechanical dyssynchrony 
without adversely effecting myocardial oxygen requirements.  The benefit of BiV 
pacing may be amplified by optimising the AV and VV pacing intervals and targeting 
LV lead placement.  Therefore, optimised temporary BiV pacing may be a therapeutic 
option to augment cardiac output after cardiac surgery, in ventilated patients receiving 
inotropes and/or intra-aortic balloon counter-pulsation (IABP).      
The question remains whether acute BiV pacing is beneficial in heart failure 
patients irrespective of baseline dyssynchrony and QRS duration and if optimisation of 
the AV and VV pacing intervals augments haemodynamic function after on-pump 
cardiac surgery.   
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1.9 Hypotheses 
 
 On-pump cardiac surgery causes both inter and intra-ventricular mechanical 
dyssynchrony. 
 Myocardial arrest with cardioplegia has a more profound effect on mechanical 
dyssynchrony in heart failure patients compared to patients with preserved LV 
function. 
 Temporary BiV and LV pacing improves haemodynamic function after cardiac 
surgery compared to atrial synchronous RV pacing. 
 BiV pacing will reduce myocardial and renal injury after on-pump surgery 
compared to standard atrial synchronous RV pacing. 
 Optimisation of the AV and VV intervals during acute temporary biventricular 
pacing improves cardiac output compared to nominal settings. 
 Assessment of the arterial pulse wave using the FloTrac device provides an 
accurate minimally invasive alternative to measurement of cardiac output using 
PA catheters. 
 
1.10 Design of the thesis 
This thesis contains three studies.  A ‘control’ study was designed to investigate 
the effects of on-pump surgery with respect to the development of mechanical 
dyssynchrony.  This study recruited patients with preserved left ventricular function 
(ejection fraction ≥45%), who were scheduled for elective on-pump surgery.  If this 
group of patients developed de novo mechanical dyssynchrony, this would support the 
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hypothesis that biventricular pacing may be beneficial after on-pump surgery, even in 
patients without baseline dyssynchrony: the results are presented in chapter 3. 
The main study enrolled patients with heart failure (ejection fraction ≤35%) who 
were scheduled to receive on-pump cardiac surgery.  Patients were randomised to 
receive either biventricular pacing or standard pacing (atrial-inhibited or dual chamber 
right ventricular pacing) after surgery.  The primary endpoint was the duration of 
intensive care defined as the time for which patients required “level 3 care” (section 
3.2.5).  All patients received left ventricular pacing wires to allow haemodynamic 
assessment of five different pacing modes in the post operative setting.  The other 
secondary endpoints included: the duration of inotropic support; the presence of post-
operative arrhythmias and the assessment of myocardial injury using NT-pro-BNP and 
TnT with BiV and standard pacing.  These results are reported in section 3.2.6. 
Finally, a haemodynamic study was conducted to compare two methods of 
measuring cardiac output.  The FloTrac/Vigelio system that measures cardiac output 
using arterial pulse wave analysis was validated against the “gold standard” pulmonary 
arterial catheter.  This is described in section 3.2.8.  
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Chapter 2 –Methods 
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2.1 Introduction 
 The first part of this chapter describes the inclusion criteria for the control study 
and the main trial of temporary biventricular pacing in patients with severe LV 
dysfunction, after on-pump cardiac surgery.  The echocardiogram protocol listed in 
table 9 was used for both studies both before and after surgery. 
 
2.1.1 Approvals 
The initial application to investigate temporary biventricular pacing after cardiac 
surgery in patients with severe LV dysfunction was approved by the Research and 
Development departments at both the University Hospital of Wales, Cardiff 
(09/CAD/4628-main sponsor) and at Morriston Hospital, Swansea, UK (S10CardS961).  
The trial was also approved by the Dyfred Powys Research Ethics Committee-
09/WMW01/27.   
A substantial amendment was subsequently approved by all parties, to 
investigate the effect of cardiopulmonary bypass on cardiac dyssynchrony using 
echocardiography in patients with preserved LV function.  All investigations were 
conducted in accordance with the ‘Declaration of Helsinki’ and all patients provided 
written consent.  These trials were registered with clinicaltrials.gov NCT01027299. 
 
2.2 Control study 
2.2.1 Introduction 
Patients awaiting elective on-pump coronary bypass surgery where invited to 
participate in this study.  Patients were required to be in sinus rhythm on the 12-lead 
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ECG prior to surgery with a transthoracic echocardiogram reporting a Simpson’s 
biplane ejection fraction ≥45%.  The principal exclusions were: permanent AF, QRS 
duration >120 ms on 12-lead ECG, critical pre-operative status with on-going 
ischaemia, or valve surgery.  All patients provided written consent to participate in this 
study. 
 
2.2.2 Echocardiography 
After written consent was obtained, a further echocardiogram was performed 
using the trial protocol, illustrated in table 9.  The echocardiogram was performed at 
least 24 hours before surgery.  The echocardiogram was repeated if the operation was 
performed 7 or more days after the original scan.  Patients proceeded to the next phase 
of the trial if their EF remained ≥45%.  For the purposes of this study, additional pacing 
wires and invasive haemodynamic monitoring were not required. 
All echocardiograms were performed using a 3.5 mHz transthoracic transducer 
and GE, Vivid 7, Horten, Norway, ultrasound scanner.  The echocardiograms were 
performed to evaluate LV systolic and diastolic function, valve function and cardiac 
dyssynchrony.  Patients were scanned in the left lateral decubitus position. 
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Table 9: Echocardiography protocol–control study  
Echo window Modality Measurement 
Parasternal long axis MMode 
 
 
Colour flow 
LV internal dimensions 
LV wall thickness 
Septum to lateral wall delay 
Mitral regurgitation 
Parasternal short axis PW Doppler 
CW Doppler 
RVOT- pulmonary pre-ejection interval (PPEI) 
PA acceleration time 
Apical 4 chamber  2D 
 
MMode 
 
Colour flow 
PW Doppler 
 
 
TDI 
LA and RA area 
LVEDV and LVESV 
Long axis displacement- RV lateral/ LV septal 
and lateral walls 
Mitral regurgitation 
Mitral inflow 
LVOT- aortic pre-ejection interval (APEI)   
LVOT- VTI 
IVRT 
Medial and lateral E’ 
Basal segments- peak velocity. 
Apical 2 chamber 2D 
TDI 
LVEDV and LVESV 
Basal segments- peak velocity. 
Apical 3 chamber TDI Basal segments- peak velocity. 
 
From these measurements a Simpson’s biplane ejection fraction and inter-
ventricular mechanical delay were calculated.  An inter-ventricular mechanical delay 
≥40 ms was considered significant.  This was calculated as the difference in time, from 
the onset of the QRS complex to the start of aortic and pulmonary ejection, measured 
using pulsed wave Doppler.   
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Tissue Doppler (TDI) 3-beat loops were acquired from the apical window to 
measure intra-ventricular mechanical delay between the basal septal and basal lateral 
walls.  Gains, filters and sector width were optimised to improve frame rates.  A time 
delay ≥65 ms between peak systolic velocities in the left ventricular septum and lateral 
wall was used as the threshold for intra-ventricular mechanical dyssynchrony (figure 2).   
 
2.2.3 Statistical analysis 
The echocardiogram protocol was repeated between day 3 and day 5 after 
surgery, after extubation and after the inotropes and vasoconstrictors had been 
discontinued.  The interest focused on any changes in mechanical dyssynchrony: 
including E;E’ ratio; inter-ventricular mechanical delay and septum to lateral wall delay 
using tissue Doppler.  The changes in mechanical dyssynchrony in this group were 
compared to the changes in dyssynchrony in the main study, using an unpaired T test.   
A paired t test was used to compare the pre and post operative measurements of 
mechanical dyssynchrony, and a p<0.05 was used for statistical significance.  A sample 
size was estimated using published data on the inter-ventricular delay in hypertensive 
patients with preserved LV function, 21±19 ms (174).  The calculation estimated that 
paired data from 8 patients would allow a 5% significance level and 80% power, to 
detect a 20 ms change in IVMD (175). 
 After the post-operative echocardiogram, the patients completed the study.   
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Figure 8: Flow diagram for control study. 
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2.3 Main study 
Patients were invited to participate in this study if they were awaiting on-pump 
coronary revascularisation, valve surgery or both and they had a LV ejection fraction on 
echocardiography ≤35%.  All patients were in sinus rhythm at the time of enrolment.  
The inclusion/exclusion criteria are documented in table 10. 
Table 10: Inclusion/exclusion criteria–main study. 
Inclusion criteria Exclusion criteria 
Age >18 years Permanent pacemaker or defibrillator 
Sinus rhythm Infective endocarditis 
Surgical revascularisation, valve surgery or 
both 
Hypertrophic cardiomyopathy 
 Off pump cardiac surgery 
 Permanent atrial arrhythmia 
 Renal failure (dialysis dependent) 
 Emergency revascularisation. 
 
After enrolment into the study, a 12-lead ECG was performed to confirm sinus 
rhythm and measure PR interval, QRS duration and morphology.   
 
2.3.1 Echocardiography 
After obtaining written consent to participate in this trial, I performed a 
transthoracic echocardiogram using the trial protocol described in table 11.  The 
echocardiogram protocol was the same for the control study and the main trial.  The 
echocardiogram was performed at least 24 hours before surgery.  The echocardiogram 
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was repeated if the operation was performed 7 or more days after the original scan.  
Patients proceeded to the next phase of the trial if their EF remained <35%. 
Table 11: Echocardiography protocol–main study  
Echo window Modality Measurement 
Parasternal long axis MMode 
 
 
Colour flow 
LV internal dimensions 
LV wall thickness 
Septum to lateral wall delay 
Mitral regurgitation 
Parasternal short axis PW Doppler 
CW Doppler 
RVOT- pulmonary pre-ejection interval (PPEI) 
PA acceleration time 
Apical 4 chamber  2D 
 
MMode 
 
Colour flow 
PW Doppler 
 
 
TDI 
LA and RA area 
LVEDV and LVESV 
Long axis displacement- RV lateral/ LV septal 
and lateral walls 
Mitral regurgitation 
Mitral inflow 
LVOT- aortic pre-ejection interval (APEI)   
LVOT- VTI 
IVRT 
Medial and lateral E’ 
Basal segments- peak velocity. 
Apical 2 chamber 2D 
TDI 
LVEDV and LVESV 
Basal segments- peak velocity. 
Apical 3 chamber TDI Basal segments- peak velocity. 
 
All echocardiograms were performed using a 3.5 mHz transthoracic transducer 
and GE, Vivid 7, Horten, Norway, ultrasound scanner.  The echocardiograms were 
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performed to evaluate LV systolic and diastolic function, valve function and cardiac 
dyssynchrony.  Patients were scanned in the left lateral decubitus position. 
From these measurements a Simpson’s biplane ejection fraction and inter-
ventricular mechanical delay were calculated.  Patients with an EF >40% were excluded 
from the study.  An inter-ventricular mechanical delay ≥40 ms was considered 
significant.   
Tissue Doppler (TDI) 3-beat loops were acquired from the apical window to 
measure intra-ventricular mechanical delay between the basal septal and basal lateral 
walls.  Gains, filters and sector width were optimised to improve frame rates.  A time 
delay ≥65 ms between peak systolic velocities in the left ventricular septum and lateral 
wall was used as the threshold for intra-ventricular mechanical dyssynchrony, see figure 
2.   
At the discretion of the consultant cardiac surgeon or cardiologist, a dobutamine 
stress echocardiography study was performed to quantify functional reserve, and 
myocardial viability using a 3.5 mHz transthoracic transducer and a GE, Vivid 7, 
Horten, Norway, ultrasound scanner.  Principal exclusions were a recent acute coronary 
syndrome or episode of decompensated heart failure (<30 days), valvular heart disease, 
or a prior viability assessment using another imaging modality.    
Viability assessments were performed with ECG and blood pressure monitoring.  
Dobutamine was initially infused at a rate of 5 µg/kg/min and increased in steps to 10, 
20, 30 and 40 µgrams every 3 minutes.  Atropine 0.25 mg was added as a bolus, at 
intervals of 1 minute, up to a total dose of 1 mg to achieve a maximum target heart rate 
= [(220-age) x 0.85].  Viability was defined as 5 or more segments with abnormal 
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resting function but manifesting contractile reserve during dobutamine testing (176, 
177).  
The echocardiogram protocol was repeated on day 3 after surgery to measure 
changes in mechanical dyssynchrony: including E:E’ ratio; inter-ventricular mechanical 
delay and septum to lateral wall delay using tissue Doppler.   
I repeated the measurements of LV and RV pre-ejection intervals and basal 
septum to lateral wall delay using TDI, 5 minutes after completing the pre-operative 
echocardiogram.  The reproducibilities of these measurements was compared to 
published data in the PROSPECT trial and a study by Thomas et al (95, 142), by 
calculating the co-efficient of variation, as described in the statistics section 2.4.6.  
 
2.3.2 Laboratory investigations 
Blood samples were obtained in the anaesthetic room prior to surgery, 
immediately after surgery and at 18 hours, 48 hours and 72 hours following the 
operation.  Measurements included urea and electrolytes, troponin T, and N-terminal 
pro b-type natriuretic peptide (NT pro-BNP).  Estimated glomerular filtration rate was 
calculated using the Cockroft-Gault formula: 
eGFR= (140-Age) x mass (kg) x constant  
     Creatinine ( mol/L) 
 
Constant: male=1.23 and female=1.04 
For measurement of NT pro-BNP, blood samples were obtained and stored on 
ice.  The sample was centrifuged for 15 minutes and the serum stored in 2 separate 
tubes at -80C.  Once all the samples had been collected they were analysed in a core lab, 
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at St George’s Hospital, London, using the IMMULITE™ 2500 analyser (Siemens, Los 
Angeles, USA). 
 
2.3.3 Randomisation 
After induction of anaesthesia, I randomised the patients into 2 groups, using a 
computer program- ‘MINIMIMS’ www.sghms.ac.uk/depts/phs/guide/randser.htm.  This 
program performed a stratified randomisation to ensure both groups had approximately 
the same number of patients with similar characteristics.  The variables taken into 
account included: LV size, ejection fraction and markers of dyssynchrony that may 
influence the post-operative response to BiV pacing.  The variables are listed in table 
12.  Only the patient was blinded to the randomisation but not the investigator.   
Group 1 was assigned to BiV pacing and group 2 to standard pacing.  Standard 
pacing was atrial inhibited pacing (AAI) unless ventricular pacing was required for AV 
block, then atrial-synchronous right ventricular pacing (DDD-RV) was programmed.  
Pacing was continued until the primary endpoint was achieved or for 48 hours, 
whichever was the longest.  
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Table 12: A list of variables that were included into the stratified randomisation. 
Parameter Reference  
LV size ≤60 mm >60 mm 
QRS duration ≤120 ms >120 ms 
Euroscore ≤10 >10 
Intra-aortic balloon pump  No Yes 
Valve surgery No Yes 
Ejection fraction  ≤20% >20% 
 
2.3.4 Operation 
All patients received peri-operative heart rhythm monitoring, pulse oximetry, 
and a radial arterial line attached to a Vigileo™ (version 1.1) cardiac output monitor 
(FloTrac™ MHD8R, Edwards Lifesciences, Dominican Rep).  A central line and a 
pulmonary arterial catheter (either 7.5F CCO: 139HF75P or 7F TD: 131 F7, Edwards 
Lifesciences, Irvine, USA) was inserted into the right internal jugular vein after 
intravenous induction of general anaesthesia.   
The anaesthetic and cardio-pulmonary bypass (CPB) technique was 
standardised.  After premedication with benzodiazepines, anaesthesia was induced with 
IV propofol (1-2 mg/kg) and fentanyl (10-20 µg/kg); muscle relaxation was achieved 
with rocuronium (1mg/kg), vecuronium (0.2mg/kg) or pancuronium bromide (0.1 - 0.2 
mg/kg).  The airway was intubated and mechanically ventilated with oxygen, air and 
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isoflurane 1-2%.  Propofol and remifentanil infusion were used in addition to isoflurane 
for maintenance of anaesthesia.   
Intravenous fluids (Hartmann’s solution or gelofusin), vasopressors 
(metaraminol or phenylephrine) and inotropes (enoximone or milirone, dopamine, 
noradrenaline or adrenaline) were titrated according to patients’ haemodynamic status.  
Prophylactic antibiotics (cefuroxime and teicloplanin) and antifibrinolytic agents such 
as tranexamic acid (2g) were administered prior to sternotomy. 
Operative monitoring was identical in all patients.  The extracorporeal circuit 
comprised of a Stockert™ roller pump (Shiley Inc, Irvine, CA), a Shiley S100™ 
membrane oxygenator, and polyvinylchloride tubes.  Patients were given heparin just 
before the institution of CPB with 300 IU/kg, with additional dosing as necessary to 
maintain the activated clotting time greater than 480 seconds.  Non-pulsatile 
extracorporeal circulation was initiated at flows of 2.4 to 2.6 L m
-2
 min
-1
.  Moderate 
systemic hypothermia (32 
0
C nasopharyngeal) was uniformly used.  Cardiac arrest was 
achieved by infusion of 1 L of cold blood cardioplegic solution and topical slush.  
Repeated doses of cardioplegia were administered as required. 
All distal anastomoses were performed during a single period of cross-clamping, 
and the proximal anastomoses to the aorta were completed during the re-warming 
period using a side-biting clamp.  Extracorporeal circulation was terminated at a 
nasopharyngeal temperature of 37
0
C.  Heparin was neutralized after the end of CPB 
with protamine sulphate (1mg/100 IU heparin).    
Before weaning from the cardio-pulmonary bypass circuit, temporary unipolar 
epicardial pacing wires were sutured to the roof of the right atrium, the right ventricular 
outflow tract and the postero-lateral free wall of the left ventricle (first obtuse marginal 
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territory) avoiding scar tissue.  There were 6 temporary pacing wires, 3 active and 3 
indifferent wires.  The wires were attached via extension cables (APC Cardiovascular 
Ltd) to a temporary external triple chamber pacemaker (Osypka PACE 300™, 
Germany).  A representative photograph and diagram of the positions of the electrodes 
in an individual patient in the trial are illustrated as figures 9 and 10.  
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Figure 9 : Position of temporary pacing wires (1=right atrium, 2=right ventricular outflow tract and 3=left ventricle, basal region of OM1).  
Two unipolar wires were attached at each site.  (Consent-appendix A). 
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Figure 10: Position of temporary pacing wires-(RA=right atrium, RV=right ventricular outflow tract and LV= basal region of OM1). 
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Pacing was commenced prior to separation from the bypass circuit according to 
each patient’s randomisation.  Subjects in the biventricular pacing group (group 1) 
received DDD-BiV pacing, base rate 90 bpm, AV interval 120 msec, maximum tracking 
rate 110 bpm, VV interval -5 msec (the negative value indicates LV pre-activation).  
The standard pacing group (group2) received AAI pacing at base rate 90 bpm unless 
ventricular pacing was indicated for high grade AV block.  In this situation DDD-RV 
pacing was programmed, base rate 90 bpm, AV interval 150 msec and maximum 
tracking rate 110 bpm.  RV pacing was kept to a minimum. 
Inotropes including enoximone or milrinone in combination with noradrenaline 
were administered according to haemodynamic requirements.  The target ranges for 
haemodynamic parameters after surgery were: 
 Mean arterial pressure 60-70 mm Hg 
 Pulmonary capillary wedge pressure <18 mm Hg 
 Cardiac index ≥2.0-2.5 L/min/m2  
 
2.3.5 Primary endpoint 
The primary endpoint of the trial was the duration of level 3 care after cardiac 
surgery (178).  Level 3 care was defined as the requirement for invasive mechanical 
ventilation, or multiple organ support, or multiple inotropes, or a single inotrope with an 
intra-aortic balloon pump.  It was anticipated that for most patients, the transition from 
level 3 to level 2 care would occur after extubation from invasive ventilation and then 
after reducing the total number of IV infusions to either a single inotrope or 
vasoconstrictor.  This is because a vasoconstrictor such as noradrenaline would 
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typically be prescribed in combination with a PDE III inhibitor to prevent post-
operative hypotension.  
An alternative scenario would be that a patient requiring haemodynamic support 
with a single IV infusion (either an inotrope or a vasoconstrictor) would reach the 
primary endpoint, after extubation from invasive ventilation.  In patients for whom the 
inotropic agents or vasoconstrictors were restarted, the endpoint was taken to be the 
final transition from level 3 to level 2 care, before discharge from the intensive care 
unit. 
I thought the transition from level 3 to level 2 care would be a more relevant 
endpoint than the total duration of ITU stay, which has been used in previous studies.  
The duration of ITU admission is limited by a number of confounding variables.  This 
includes: the availability of beds on a step-down ward; the time of admission to ITU and 
the frequency of ward rounds to make plans for extubation from invasive ventilation 
and reducing the dose of IV inotropes and vasoconstrictors.  These confounding 
variables can be removed by using this level of care model.   
 
2.3.6 Sample size 
Pokushalov et al (138),  reported a 36% reduction in mean ITU admission with 
BiV pacing compared to standard pacing (no LV pacing) after surgery, (2.5 ± 0.5 days 
compared to 3.9 ± 0.6 days: p <0.001 respectively).  I anticipated that the duration of 
level 3 care would be shorter than the duration of ITU admission, perhaps with less 
variance, but we used these mean values and standard deviations for our power 
calculation.   
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Using the standard formula described by Campbell and Matchin (175): 
Sample size = 2 x (Z1α + Z2β)
 2 x σ2    
                δ2  
σ = standard deviation of the population 
δ = anticipated benefit from the intervention 
(Z1α + Z2β) = normal distribution of function 
(1-β) = 80% and α = 5%. 
From standard tables (Z1α + Z2β)
 2
 = 7.85 
Sample size = 2 x (7.85) x 0.6
2
   = 5.652 = 16.5  
     (0.15 x 3.9)
2 
               0.342 
 
In order to demonstrate a 15% reduction in the duration of  level 3 care, with a 
power of 80% and with p<0.05 for a two-sided statistical significance, an estimated 
sample size of 34 patients was required. 
 
2.3.7 Haemodynamic data 
Haemodynamic data were collected using a pulmonary arterial catheter on 
admission to ITU and 6 hours and 18 hours after admission.  This included measuring: 
 Cardiac output/ index (L/min and L/min/m2) 
 Left ventricular stroke work index (g/m2/beat) 
 Mean arterial blood pressure (mm Hg) 
 Pulmonary arterial pressures -systolic/diastolic/ mean (mm Hg) 
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 Pulmonary capillary wedge pressure (mm Hg)    
 Systemic vascular resistance (dynes-sec/cm-5) 
 
These measurements were taken in 5 different pacing modes: 
 Biventricular pacing (DDD-BiV) 
 Atrial inhibited pacing (AAI) 
 Dual chamber right ventricular pacing (DDD-RV) 
 Dual chamber left ventricular pacing (DDD-LV) 
 Right ventricular pacing only (VVI) 
The baseline pacing rate was 90 beats per minute but increased to 10 beats above 
intrinsic rate for the haemodynamic studies up to a maximum heart rate of 110 beats per 
minute.  For BiV pacing the AV interval was set at 120 ms (VV interval = -5 ms, -ve 
indicating LV pre-activation) and 150 ms for DDD-RV and DDD-LV pacing with a 
target of 100% ventricular pacing.  If intrinsic rhythm or fusion was observed, the AV 
interval was shortened by 10 msec until a paced ventricular rhythm was observed on the 
monitor.   
Haemodynamic data were recorded 5 minutes after changing pacing mode.  For 
thermodilution measurements, a minimum of 3 measurements were obtained.  The data 
were assessed for accuracy by reviewing the thermodilution curves.  If the cardiac 
output measurements lacked agreement (range ≥0.5 L/min) then 2 additional 
measurements were taken.  The median value of the 5 readings was calculated.  Cardiac 
output measurements ≥0.5 L/min from the median value were rejected as outlying 
results.  For continuous cardiac output monitoring, the cardiac output was averaged for 
3 cycles (1 cycle per minute). 
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At 18 hours, cardiac output measurements were also taken using the FloTrac 
device (arterial wave-form contour analysis) for AV and VV optimisation.  The Flotrac 
device was used as it allowed a rapid assessment of cardiac output and reduced the 
volume of saline administered via the PA catheter by 500 ml.  Cardiac output was 
measured for a range of AV intervals from 80-200 ms in 20 ms intervals and VV range -
40 to +40 ms in 20 ms intervals.   
The optimal AV and VV intervals were programmed for the BiV pacing group 
(group 1).  After each set of haemodynamic studies, the base rate of pacing was reduced 
to 90 beats per minute and the AV interval was reset to 150 ms in the DDD-RV group 
(group 2).  
 
2.3.8 Haemodynamic comparison PA v FloTrac 
 All patients in the main trial received a PA catheter.  The device was inserted 
into the SVC in the anaesthetic room before surgery and then advanced into the PA in 
the cardiac intensive care unit.  In addition, all patients received a radial arterial line. A 
FloTrac sensor (MHD8, Edwards Lifesciences, Irvine, CA, USA) was attached to the 
radial arterial line in all patients except those with intra-aortic balloon pumps.  The 
FloTrac sensor (3
rd
 generation) was attached to a Vigileo monitor (V1.1, Edwards Life 
sciences, Irvine, CA, USA) to calculate cardiac output using arterial waveform analysis.  
Simultaneous measurements of cardiac output were taken using either a 
thermodilution or continuous cardiac output PA catheter (either 7.5F CCO: 139HF75P 
or 7F TD: 131 F7, Edwards Lifesciences, Irvine, USA) used in the main trial.  
Measurements of cardiac output were taken at baseline, 6 hours, and 18 hours after 
surgery in 5 different pacing configurations (AAI, VVI, DDD-RV, BiV and DDD-LV) 
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as previously described.  The infusion rates of inotropes and vasopressors were kept 
constant while performing haemodynamic measurements.  For thermodilution, a 
minimum of 3 measurements was taken 5 minutes after changing pacing mode to ensure 
consistent results were obtained.  Outlying results were discarded as described in 
section 2.3.7.  
The results obtained were compared using linear regression (Pearson co-
efficient).  A Bland-Altman plot and an agreement of methods was assessed as 
recommended by Critchley and Critchley (164).  The agreement of methods was 
assessed by calculating the percentage error for the cardiac output measurements 
obtained using the PA catheters and FloTrac system.   
  To calculate the percentage error: 
1. Calculate the mean cardiac output obtained from the PA catheter and 
Flotrac device. 
2. The bias (µ) of the Flotrac device is the difference between the CO 
measured using the Flotrac device and the mean cardiac output.  
3. The standard deviation of the individual bias measurements is then used 
to calculate 95% confidence intervals (= µ ± 2xSD). 
4. The percentage error is calculated (= ± 2xSD/mean cardiac output of 
both methods).      
The standard error of measurement using a thermodilution PA catheter is 
reported to be 10-20%.  Therefore, limits of agreement between the PA catheter and 
FloTrac device can be established if the percentage error is less than 30%: 
Percentage error = Square root (20
2
 + 20
2
) = 28.3% (approximately 30%). 
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2.3.9 Feasibility study 
The surgical databases at the University Hospital of Wales (UHW), Cardiff, and 
Morriston Hospital, Swansea, were analysed for the number of patients in sinus rhythm 
with severe LV dysfunction (EF ≤30%), who had cardiac surgery in 2005.  At UHW, 14 
subjects in sinus rhythm with severe LV systolic dysfunction (EF ≤30%) had cardiac 
surgery.  At Morriston Hospital, 45 subjects fulfilled these criteria.   
Each year approximately 60 subjects would be potential candidates for the post-
operative BiV pacing trial.  If 50% of available subjects consented to the study and the 
dropout rate was 30%, then 41 subjects should complete the study over 2-years.  This 
would satisfy the sample size calculation (n=34).  Patients were therefore recruited from 
both surgical centres.     
 
2.4 Statistical methods 
 I performed all the analyses using the intention-to-treat principle.  Baseline 
characteristics were averaged and displayed as arithmetic means with standard 
deviations for continuous variables.  Counts and percentages for categorical variables 
were compared using a two-sample t-test, a chi-squared test or Fisher’s exact test.  All 
the data were analysed using IBM SPSS version 18, statistical software.    
  
2.4.1 Primary endpoint 
A time-to-event analysis was performed for the duration of level 3 care, as the 
data were not normally distributed.  The distribution of the data was assessed using a 
histogram.  The primary endpoint was displayed using a Kaplan-Meier plot.  A log-rank 
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test was performed to assess for statistical significance between the two pacing groups.  
A Cox-regression analysis was used to calculate hazard ratios and 95% confidence 
intervals. Linear regression analysis was performed to investigate the relationship 
between baseline characteristics including electrical and mechanical dyssynchrony with 
respect to the primary endpoint.  The methods used to assess the primary endpoint were 
reviewed and approved by Mr Hills, Department of Medical Statistics, Cardiff 
University during the open-access study day 2012.   
 
2.4.2 Haemodynamic monitoring 
The haemodynamic data were compared between pacing groups: at baseline, 6 
hours and 18 hours after admission to cardiac ITU using a repeated measures ANOVA 
test for within-subjects effects.  A p value <0.05 implied significance.  The relationship 
between groups was further investigated with a two-sided, paired Student t test.  
Comparisons were made for cardiac output and cardiac index, LV stoke work index, 
mean arterial pressure (MAP), pulmonary arterial pressure (PAP) and pulmonary 
capillary wedge pressure (PCWP).  The principal comparisons were between BiV v 
AAI pacing and BiV v DDD-RV pacing.   
A Bonferroni correction was applied to allow for multiple comparisons between 
the groups with a p value ≤0.25 implying statistical significance.  A linear regression 
analysis was also performed to investigate the significance of baseline dyssynchrony in 
predicting an acute haemodynamic response to BiV pacing.  The nominal v optimal AV 
and VV pacing intervals were compared using a paired Student t test.   
The correlation between the measurements of cardiac output using the PA 
catheter and the FloTrac device was assessed using a Pearson correlation co-efficient (r) 
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and systematic bias was reported using a Bland-Altman analysis.  A p value <0.05 
implied statistical significance. 
 
2.4.3 Haemodynamic support 
The total duration (hours) of inotropic support and the total dose per Kg of each 
infusion were calculated for both groups of patients.  The results were expressed as 
means with standard deviations.   After assessing for normal distribution, an unpaired 2-
sided Student t test was used to assess for significance between the two groups, a p 
value <0.05 implied statistical significance. 
 
2.4.4 Biochemical tests 
Blood samples were taken in the operating theatre: before induction; on 
admission to cardiac intensive care unit; and at 18 hours, 48 hours and 72 hours after 
admission for serum creatinine, troponin T and NT-pro-BNP.  Estimated glomerular 
filtration rate was calculated using the Cockroft-Gault formula.  The requirement for 
post-operative haemofiltration was also recorded.   
Continuous variables between the 2 groups was analysed using an unpaired t 
test.  For NT-pro-BNP, a non-parametric test was used; the Wilcoxon Signed Rank Test 
because the values were not normally distributed.  A p value <0.05 implied statistical 
significance.  
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2.4.5 Arrhythmias 
Patient telemetry was used during the ITU and HDU admission. A 48-hour 
Holter monitor was attached to each patient on arrival to ITU.  I reviewed the tapes in 
the physiology department.   
All atrial and ventricular arrhythmias were recorded if they lasted over 30 
seconds.  A Chi squared test was used to compare the number of arrhythmic episodes in 
each group, a p value <0.05 implied statistical significance. 
 
2.4.6 Echocardiography 
The transthoracic echocardiograms were performed before the operation and on 
post-operative day-3 using the echocardiogram protocol described in table 11.  Changes 
in diastolic function (E:E’ ratio), inter-ventricular mechanical delay and LV septum to 
lateral wall delay using tissue Doppler were compared before and after surgery using a 
paired t test.  A p value <0.05 implied statistical significance. 
 
2.4.7 Reproducibility  
An intra-observer co-efficient of variation (CV %) was calculated for the 
measurements of   mechanical dyssynchrony, including aortic and pulmonary pre-
ejection intervals and LV septum to lateral wall delay using tissue Doppler.  The co-
efficient was calculated using the formula:  
CV=  (SD2/arithmetic mean of measurements) x 100 
SD2= the standard deviation of residuals (measurement 1- measurement 2).  
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2.5 Safety data 
Post-operative re-sternotomy for bleeding along with any complication related to 
a temporary pacing wire or pulmonary arterial catheter was reported to the sponsor and 
ethics committee.  Total mortality was recorded up to the end of the trial at 30-days. 
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Chapter 3- Results 
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3.1 Control study 
Between May 2011 and January 2012, 13 subjects provided written consent to 
participate in the control study.  10 patients completed the protocol.  Two patients 
declined the second post-operative echocardiogram and one patient was discharged 
before the study could be performed.  The baseline characteristics are illustrated in table 
13.  This group of patients were at low risk of surgical complications with a Euroscore 1 
of 4.0±2.6 and QRS duration was 84.5±6.5ms.  All patients had a QRS duration less 
than 120 ms and only one patient had a PR interval above 200 ms (285 ms). 
All patients had on-pump coronary artery bypass surgery and received an 
internal mammary graft and 2±0.5 vein grafts.  No valve replacements or repairs were 
performed.  The mean cardio-pulmonary bypass time and aortic cross clamp time were 
95.3±17.5 and 70.3±24.7 minutes respectively.      
Baseline echocardiography showed preserved LV systolic function with a mean 
EF 54.3±6.0%.  There was no evidence of baseline mechanical dyssynchrony: inter-
ventricular mechanical delay <40 ms and intra-ventricular mechanical delay <65 ms, for 
all patients.  There was a 23% reduction in diastolic filling time after cardiac surgery 
(70.8±7.6 ms v 54.8±31.8 ms; p=0.02, before v after surgery) but no change in inter or 
intra-ventricular mechanical delay or isovolumic relaxation time.  All patients 
developed a paradoxical motion of the inter-ventricular septum after cardiac surgery; 
see figure 11 and table 14.   
Therefore, after on-pump cardiac surgery, patients with preserved LV systolic 
function only developed subtle changes in diastolic and systolic function.       
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Figure 11:  Tissue tracking of the basal septum and posterior wall after bypass surgery, 
illustrating a paradoxical motion of the ventricular septum. Yellow marker 
indicates septal wall motion and green marker posterior wall motion. 
  
94 
 
Table 13: Baseline characteristics–control study. 
Parameter Reference (n=10) 
Age 65.6±10.7 
Male gender (%) 70 
Euroscore 1 4.0±2.6 
Smoker (n)  3 
Hypercholesterolaemia (n) 8 
Diabetic (n) 1 
Hypertensive (n) 8 
Aspirin (n) 7 
Beta Blocker (n) 7 
ACE inhibitor (n) 8 
Statin (n) 10 
ECG: sinus rhythm (n) 10 
PR interval (ms) 174±44.3 
QRS duration (ms) 84.5±6.5 
Paroxysmal AF (n) 0 
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Table 14: Echocardiographic measurements before and after on-pump surgery. 
Parameter Before surgery After surgery p value  
LV end diastolic dimension (cm) 4.8±0.5 4.4±0.6 0.06 
Pulmonary pre-ejection interval (ms) 83.3±11.2 77.8±15.3 0.34 
Aortic pre-ejection interval (ms) 87.5±10.8 85.8±14.3 0.80 
Inter-ventricular mechanical delay (ms) 4.2±10.9 8.0±18.0 0.44 
Diastolic filling time (ms) 70.8±7.6 54.8±16.3 0.02 
Pulmonary acceleration time (ms) 98.0±12.2 91.5±31.8 0.50 
Left atrial area (cm
2
) 17.7±3.5   
Right atrial area (cm
2
) 14.3±2.7   
Mitral valve E wave (m/s) 0.7±0.1 0.75±0.1 0.70 
Mitral valve A wave (m/s) 0.8±0.1 0.72±0.1 0.14 
E:A ratio 0.9±0.3 1.0±0.3 0.11 
E:E’ ratio 7.1±1.6 8.1±3.2 0.35 
Isovolumic relaxation time (ms) 102.3±19.4 89.2±17.0 0.17 
End-diastolic volume (ml) 101.1±26.3   
End-systolic volume (ml) 47.1±17.6   
Ejection fraction (%) 54±6.0   
Intra-ventricular mechanical delay (ms) 49.1±35.0 41.6±32.0 0.40 
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3.2 Main study 
Between January 2010 and July 2012, 55 patients with severe LV systolic 
dysfunction gave written consent to participate in the post operative BiV pacing trial.  
38 subjects completed the trial protocol and 17 subjects exited the study (figure 12).  
Four patients were removed at the request of the surgical team because of planned 
intervention to the tricuspid valve. 
Figure 12: Flowchart for patients excluded from the trial. 
 
   55 patients 
Request of cardiac surgeon (n=4) 
    Simultaneous operations at different hospitals (n=3) 
    Procedure changed to off pump cardiac surgery (n=2) 
    Referred for angioplasty (n=2)  
    Ejection fraction improved ≥40 (n=2) 
    Emergency CABG (n=1) 
    Palliative care (n=1) 
    Unable to float pulmonary arterial catheter (n=1) 
    Latex allergy- could not use PA catheter (n=1) 
38 patients 
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3.2.1 Pre-operative data 
The baseline demographics for the 38 patients who completed the trial are 
illustrated in table 15.  The 2 groups were well matched.  For all participants, the mean 
age was 67.4 ±11.4 years and 79% were male.  31/38 (82%) had NYHA class II or III 
heart failure.  The majority of patients 32/38 (85%) had a prior myocardial infarction 
and 13/38 (34%) had an acute coronary syndrome within 30-days before surgery. 
All patients were in sinus rhythm on the pre-operative ECG with an ejection 
fraction ≤ 35% before surgery.  9 patients had previously documented episodes of atrial 
fibrillation.  None of the patients entering into the trial required haemodialysis.  28/38 
(74%) of patients had a Chronic Kidney Disease (CKD) score 1 or 2 with an estimated 
glomerular filtration rate ≥60 ml/min/1.73m2.  Pre-operative beta blockers were 
continued prior to surgery but ACE-I were discontinued in 11/20 (55%) patients.  
The baseline ECG confirmed 7/38 (18%) patients had first degree AV block (PR 
interval ≥ 200ms) and 10/38 (26%) had a QRS duration ≥120 ms and left bundle branch 
block. 
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Table 15: Clinical characteristics of the patients enrolled into the main trial.  
Demographic Biventricular pacing  (n=19) 
Group 1. 
Standard pacing (n=19) 
Group 2 
p 
Age (years) 69.2 ±9.3 65.5 ±12.7 0.32 
Male (%) 79 79 1.0 
NYHA score 2.5 ±0.7 2.4 ±0.9 0.18 
CCS score 1.9 ±0.9 1.8 ±0.8 0.71 
Euroscore 1 8.3 ±3.1 7.0 ±2.8 0.18 
ACE-I (%) 58 47 0.52 
Beta blocker (%) 63 84 0.14 
Diabetic (%) 10 37 0.06 
Paroxysmal AF (%) 5 16 0.33 
Prior CVE (%) 20 11 0.34 
Prior MI (%) 80 89 0.37 
CKD score 2.2 ±0.9 1.9 ±0.6 0.28 
LVEF (%) 26.1 ±5.4 28.0 ±7.3 0.38 
PR interval (ms) 176 ±30 174 ±28 0.87 
QRS duration (ms) 113.3 ±29.3 115.2 ±24.4 0.84 
LBBB (%) 24 29 0.40 
LMS (≥50%), (n) 2 6 0.11 
Prox LAD (≥70%), (n) 9 11 0.52 
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3.2.2 Echocardiographic data 
Table 16 contains the pre-operative transthoracic echocardiographic 
measurements and calculations.  The stratified randomisation produced two well 
matched groups for LV dimensions, systolic function and markers of mechanical 
dyssynchrony.  4/38 (11%) patients had an ejection fraction <20% and 8/38 (21%) had 
raised LV end-diastolic filling pressures (E/E’ ≥15).  11/38 (29%) patients had severe 
LV dilatation (end-diastolic volume; ≥202 ml for males and ≥131 ml for females) (179). 
10/38 (26%) of patients had an intra-ventricular mechanical delay ≥65ms 
(difference in time to peak basal septum and lateral wall velocities) and 26% had an 
inter-ventricular mechanical delay ≥40 ms, (difference in time of onset of pulmonary 
and aortic ejection period).  Overall, prior to surgery, 61% of patients had evidence of 
either electrical or mechanical dyssynchrony.   
Dobutamine stress echocardiography (DSE) was only performed in 2/38 (5%) 
patients.  2/38 (5%) patients had a PET viability scan and subsequently had surgical 
revascularisation.  In total, 4/38 (10%) patients had a viability assessment before 
surgery.  The other reasons for not performing a viability test included concomitant 
valvular heart disease in 10/38 (26%) patients and 3 patients had unstable angina before 
surgery.  Left main stem stenosis >50% or proximal left anterior descending artery 
stenosis >70% excluded 9 patients from having a DSE.  9 patients received an intra-
aortic balloon pump, which was another contra-indication to viability assessment.        
 
  
100 
 
Table 16: Data from transthoracic echocardiogram before cardiac surgery. 
Demographic Group 1 (n=19) Group 2 (n=19) p 
LVEDD (cm) 5.7±0.8 5.4±1.4 0.46 
End-diastolic volume (ml) 173.9±66.5 161.0±39.2 0.47 
End-systolic volume (ml) 132.6±65.2 115.6±29.0 0.30 
Ejection fraction (%) 26.1±5.4 28.0±7.3 0.38 
LA area (cm
2
) 20.8±5.6 20.1±5.9 0.70 
RA area (cm
2
) 16.0±6.8 14.5±4.6 0.43 
Mitral inflow: E wave velocity (m/s) 0.77±0.32 0.86±0.33 0.41 
Mitral inflow: A wave velocity (m/s) 0.72±0.34 0.75±0.24 0.79 
Mitral inflow: E:A ratio 1.60±1.26 1.44±0.97 0.67 
Mitral inflow: E deceleration time (ms) 235.8±89.1 222.2±105.2 0.67 
TDI: E’ (cm/s) 7.1±0.02 7.3±0.04 0.81 
Ratio E:E’ 12.6±7.6 13.0±9.1 0.90 
Isovolumic relaxation time (ms) 100.6±37.7 128.3±41.2 0.20 
LV: lateral annulus excursion (cm) 0.74±0.35 0.90±0.30 0.19 
LV: medial annulus excursion (cm) 0.61±0.15 0.79±0.33 0.06 
RV: tricuspid annulus excursion (cm) 2.1±0.38 1.94±0.60 0.35 
Pulmonary pre-ejection interval (ms) 96.8±24.6 82.0±22.2 0.07 
Aortic pre-ejection interval (ms) 105.2±23.2 109.3±40.4 0.70 
Inter-ventricular mechanical delay (ms) 19.7±22.2 26.4±39.6 0.53 
Inter-ventricular mechanical delay ≥40ms (n) 6 4 0.46 
 TDI: septum-lateral wall delay/ (n≥65ms) 6 4 0.46 
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3.2.3 Operation 
 All 38 patients had on-pump cardiac surgery.  33/38 (87%) had 
revascularisation, and 15/38 (39%) had valve surgery.  There were no differences  
between the groups with respect to the number of bypass grafts created, the use of 
arterial conduits or the duration of cardio-pulmonary bypass or aortic cross clamp time.  
All patients received cold blood cardioplegia via anterograde catheters with 2/38 (5%) 
receiving both anterograde and retrograde cardioplegia, see table 17. 
Table 17: Revascularisation and valve surgery performed during the trial. 
Demographic Group 1 (n=19) 
BiV pacing 
Group 2 (n=19) 
Standard pacing 
p 
CABG (n) 12 11 0.74 
CABG and Valve (n) 4 6 0.46 
Valve only (n) 3 2 0.63 
Valves replaced: 
Aortic only 
Mitral only 
Both (aortic and mitral) 
 
5 
0 
1 
 
6 
2 
0 
NS 
IABP (n)  5 4 0.70 
Internal mammary graft (n) 13 15 0.46 
CPB time (min) 127.1±41.4 144.2±45.9 0.25 
Aortic clamp (min) 86.2±33.6 89.5±27.6 0.43 
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 All patients received 6 temporary pacing wires (3 active and 3 indifferent wires) 
prior to separation from the cardio-pulmonary bypass circuit.  The active wires were 
attached to the right atrial appendage, the right ventricular out-flow tract and the basal 
posterolateral LV wall in 37/38 (97%) cases.  In one patient, the LV wire had to be 
placed in a more anterior location because of scar tissue in the region of the first obtuse 
marginal artery.  The average duration of BiV pacing was 22.7±8.8 hours in group 1. 
 BiV pacing was successfully initiated on separation from the bypass circuit in all 
19 patients in group 1.  Phrenic nerve stimulation was observed in 3/19 (16%) of 
patients.  In two patients this complication was resolved by reducing the LV pacing 
voltage to prevent phrenic nerve stimulation while preserving BiV capture.  In one 
patient, BiV pacing was terminated after extubation because of phrenic nerve 
stimulation. 
 
3.2.4 Mechanical dyssynchrony 
Mechanical dyssynchrony did not significantly change after on-pump cardiac 
surgery in patients with impaired LV function, see table 18.  The analysis included 
measurements of systolic dyssynchrony (inter and intra-ventricular mechanical delay) 
and diastolic function (E:E’) described in section 2.3.1.  The post-operative 
measurements were obtained after discharge from the intensive care unit and after 
completing the pacing studies.  None of the patients required ventricular pacing during 
the post-operative echocardiogram.  
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Table 18: Changes in mechanical dyssynchrony before and after cardiac surgery– 
impaired LV systolic function (EF≤ 35%). 
Marker of Dyssynchrony Pre-Op Post-Op P 
Pulmonary pre-ejection (ms) 87.8±27.1 85.3±32.5 0.74 
Aortic pre-ejection (ms) 109.2±32.7 112.7±39.7 0.62 
Inter-ventricular mechanical interval (ms) 23.7±39.3 27.4±28.7 0.64 
E:E’ ratio 13.7±10.1 12.6±4.9 0.60 
TDI- LV septum to lateral wall delay (ms) 55.6±21 62.6±41 0.90 
 
However, comparing the pre-operative data in patients with impaired LV 
systolic function to the control group, aortic pre-ejection period but not inter-ventricular 
mechanical delay and the ratio of E:E’ were prolonged in the impaired LV systolic 
function group, see table 19.  Aortic pre-ejection was prolonged by 25% longer and 
E:E’ almost doubled in the impaired LV systolic function group compared to the control 
sample of patients. 
  The wide standard deviation and limited sample size may explain why the 
difference in inter-ventricular mechanical interval did not reach statistical significance.  
The intra-ventricular mechanical delay did not change in the impaired LV group after 
surgery and baseline measurements were similar in the control and impaired LV groups.  
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Table 19: Mechanical dyssynchrony before cardiac surgery in patient with impaired v 
preserved LV systolic function.   
Marker of Dyssynchrony Impaired LV 
(EF≤35%) 
Preserved LV 
(EF≥45%) 
p 
Pulmonary pre-ejection (ms) 87.8±27.1 83.3±11.2 0.29 
Aortic pre-ejection (ms) 109.2±32.7 87.5±10.8 0.04 
Inter-ventricular mechanical interval (ms) 23.7±39.3 4.2±10.9 0.24 
E:E’ ratio 13.7±10.1 7.1±1.6 0.04 
TDI- LV septum to lateral wall delay (ms) 55.6±21 49.1±35 0.84 
 
The final observation was that all patients developed a paradoxical motion of the 
ventricular septum after bypass surgery.  This was also noted in the control study.  In all 
cases after surgery; the pericardium was left open, see figure 11.   
 
3.2.5 Duration of level 3 care 
 The duration of level 3 care was not normally distributed (figure 13).  The 
median duration of level 3 care was 22.0 (IQR: 16.0-66.5) hours and 37.5 (IQR: 16.3-
55.0) hours in group 1 and 2 respectively (log-rank p=0.58, 95% CI: 0.43-1.61), see 
figures 13 and 14.   
One subject in group 1 had a premature discontinuation of BiV pacing due to 
phrenic nerve stimulation and one patient in group 2 received BiV pacing at the request 
of the attending consultant.  Only one subject in group 1 had transient second degree 
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heart block after aortic valve surgery.  No patients required a permanent pacing system 
for heart block before discharge from hospital. 
 30 patients reached the primary endpoint after extubation followed by reducing 
the number of infusions to either a single inotrope or vasoconstrictor.  8 (21%) patients 
only required a single infusion after surgery, and therefore reached the primary endpoint 
after extubation from invasive ventilation. 
 
Figure 13: Histogram for the duration of level 3 care for all patients. 
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Figure 14: Duration of level 3 care in the two treatment groups-individual plots. 
 
Two patients in group 2 had a prolonged duration of level 3 care: one patient had 
post-operative cardiac tamponade requiring re-sternotomy and removal of clots with 
subsequent haemofiltration, and the other required prolonged inotropic support with 2 
infusions for 238 hours despite being extubated at 10 hours.   
One patient in group 1 developed atrial fibrillation and required 129.5 hours of 
level 3 care and haemofiltration.  Excluding these outliers would reduce the duration of 
level 3 care to 21.1 (IQR: 15.3-62.3) hours in group 1 and 27.0 (IQR: 15.0-49.0) hours 
in group 2 (log-rank p=0.95). 
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Figure 15: ‘Time-to-event’ Kaplan-Meier plot for the primary endpoint/hours (p=0.58; 
95% CI 0.43-1.61). 
 
There was no association between the baseline QRS duration or the presence of 
electro-mechanical dyssynchrony and the duration of level 3 care, see figures 16-21. 
 
 
 
108 
 
Figure 16: Relationship between QRS duration and duration of level 3 care.  Pearson’s 
correlation co-efficient r=0.25, (p=0.14). 
 
 
Figure 17: Group 1- Relationship between QRS duration and duration of level 3 care.  
Pearson’s correlation co-efficient r=0.38, (p=0.12). 
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  Figure 18: Group 2- Relationship between QRS duration and duration of level 3 care.  
Pearson’s correlation co-efficient r=0.20, (p=0.42). 
 
 Using Cox regression analysis, the duration of level 3 care was not associated 
with: the QRS duration (p=0.14, 95% CI: 0.98-1.00): the presence of dyssynchrony 
(p=0.85, 95% CI: 0.49-1.81): pacing group assignment (p=0.53, 95% CI 0.39-1.63) or 
heart valve surgery (p=0.43, 95% CI: 0.66-2.64).  However, only 10 patients had a QRS 
duration greater than 120 ms and a larger sample size would have been desirable to 
exclude a type II statistical error. 
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Figure 19: Relationship between baseline dyssynchrony and duration of level 3 care.   
 
Median duration of level 3 care 42.5(IQR: 16.3-58.0) hours v 46.3 (IQR: 15.3-
58.8) hours for no dyssynchrony v baseline dyssynchrony respectively. 
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Figure 20: Duration of level 3 care (hour) in patients without baseline dyssynchrony.  
Group 1, 21.0 (IQR: 16.6-48.8) hours v Group 2, 49.0 (IQR: 16.3-66.0) 
hours. 
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Figure 21: Duration of level 3 care (hour) in patients with baseline dyssynchrony.  
Group 1, 24.4 (IQR: 15.3-73.8) hours v Group 2, 26.5 (IQR: 17.0-38.9) 
hours.   
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3.2.6 Haemodynamic data 
 Haemodynamic data were collected on admission to cardiac ITU and at 6 and 18 
hours thereafter, see table 20.  This included: cardiac output (CO), cardiac index (CI),  
LV stroke work index (LVSWI), mean arterial blood pressure (MAP),  central venous 
pressure (CVP), mean pulmonary artery pressures (PAP), systemic vascular resistance 
index (SVRI) and pulmonary capillary wedge pressure (PCWP). 
 Using the repeated measures statistic (ANOVA) the pacing modes were 
compared for significant differences in cardiac output at all 3 time points.  The F scores 
were 26.8, 17.5 and 26.0 at baseline, 6-hours and 18 hours respectively and p <0.001 for 
all comparisons.  The groups were then further analysed to identify the superior modes 
of pacing using a paired T test with a Bonferroni correction. 
At baseline (time=0) and 6 hours after the operation, cardiac output and index 
were similar for all pacing modes except right ventricular-only (VVI) pacing which was 
inferior to all other pacing modes due to loss of AV synchrony (p<0.001), see table 20.  
Cardiac output was 16-19% lower with right ventricular-only (VVI) pacing compared to 
the other pacing modes (p<0.001).  
However, at 18 hours BiV pacing was superior to all other pacing modes 
(p=0.02 compared to atrial-inhibited (AAI); p<0.001 compared to right ventricular-only 
(VVI); p=0.001 compared to dual chamber-RV and p=0.003 compared to dual chamber-
LV), see figures 22-23.  BiV pacing increased cardiac output by 7% compared to atrial-
inhibited (AAI), dual chamber-RV and dual chamber-LV pacing mode.  
BiV pacing also increased cardiac index by at least 10% at 18 hours, (p=0.02 
compared to atrial-inhibited (AAI) pacing and p<0.001 for all other pacing modes).  LV 
stroke work index was similar for all pacing modes at baseline and 6 hours with the 
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exception of right ventricular-only (VVI) pacing (p <0.001 for all comparisons).  At 18 
hours, BiV pacing improved LV stroke work index by 12% compared to dual chamber-
RV (p<0.001); by 39% compared to right ventricular-only (VVI) (p<0.001); and by 9% 
compared to dual chamber-LV (p=0.02).  There was no significant improvement in LV 
stroke work index with BiV pacing compared to atrial-inhibited (AAI) pacing mode 
(p=0.15).  BiV pacing did not influence mean arterial pressure, pulmonary arterial 
pressure or pulmonary capillary wedge pressure at 18 hours, with the exception of right 
ventricular-only (VVI) pacing.  Right ventricular-only (VVI)  pacing decreased cardiac 
output by 16-19%, cardiac index by 15-20% and LV stroke work index by 31-39% (p 
<0.001 for all comparisons). 
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Table 20: Haemodynamic data obtained from PA catheters (mean values ±SD).  
 
 
Measurement Time AAI VVI (RV) DDD-RV DDD-BiV DDD-LV 
Cardiac output 0 5.1±1.9 4.3±1.8† 5.1±1.8 5.0±1.8 5.0±2.0 
(L/min) 6 5.9±1.6 4.8±1.7† 5.6±1.7 5.8±1.6 5.7±1.6 
 18 
 
5.4±1.1 4.4±1.1† 5.3±1.1 5.8±1.2* 5.4±1.2 
Cardiac index 0 2.7±0.9 2.3±0.8† 2.7±0.8 2.7±0.9 2.7±1.0 
(L/min/m
2
) 6 3.1±0.8 2.5±0.8† 3.0±0.7 3.0±0.7 3.0±0.7 
 18 
 
2.8±0.6 2.3±0.6† 2.8±0.6 3.1±0.7* 2.8±0.7 
LVSWI 0 26.6±12.8 18.4±5.4† 24.6±7.4 24.1±8.2 23.6±8.9 
(g/m/m
2
) 6 25.9±6.7 19.0±6.6† 24.2±6.6 24.1±6.2 24.3±6.5 
 18 
 
26.3±7.3 17.3±5.3† 24.7±6.4 28.2±7.2δ 25.7±7.6 
MAP 0 73.6±10.0 60.0±10.8† 73.6±10.1 72.7±8.6 72.3±10.6 
(mm Hg) 6 73.4±8.4 65.3±13.6† 71.3±9.6 70.8±9.3 73.9±10.3 
 18 
 
73.4±11.1 63.3±9.2† 73.5±9.6 75.9±8.2 73.9±8.5 
CVP 0 9.6±4.4 11.1±5.4 11.1±4.5 9.7±4.3 9.9±4.1 
(cm) 6 11.7±3.9 11.2±3.5 10.7±4.3 10.8±4.9 10.8±4.5 
 18 
 
10.4±3.7 11.6±3.8 11.1±4.2 10.8±3.7 10.8±4.1 
PAP 0 22.4±6.4 22.1±6.1 24.1±6.4 23.5±6.0 22.1±5.7 
(mm Hg) 6 26.3±7.0 23.5±8.4 25.4±7.1 26.3±7.3 25.0±7.3 
 18 
 
21.3±6.9 22.2±6.1 22.5±6.8 22.1±6.8 21.3±5.7 
SVRI 0 2235±563 2294±858 2166±882 2066±772 2292±1097 
(dyne s/cm
-5
/m
-2
) 6 1702±583 2107±1033 1749±761 1688±574 1735±746 
 18 
 
1754±563 1962±681 1786±449 1714±654 1863±589 
PCWP 0 10.8±4.7 10.4±5.3 10.1±4.6 11.1±4.7 10.8±4.5 
(mm Hg) 6 13.3±6.3 12.4±7.3 12.7±6.7 13.6±6.6 12.8±6.5 
 18 11.7±3.9 11.1±3.6 12.0±3.4 12.0±3.6 11.8±3.4 
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Key: † p <0.001 compared to other pacing modes.  
* p <0.05 compared to other pacing modes. 
δ p <0.05 compared to other pacing modes except AAI pacing (p=NS).  
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Figure 22: Cardiac output (L/min ±SEM) in the 5 different pacing modes.  
 
Key:  *= p<0.05 for all pacing modes compared to BiV mode.  
**=p<0.001 for all pacing modes compared to VVI mode
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Figure 23: Comparison of cardiac outputs (L/min ±SD) using 5 pacing modes at 18 
hours.  p=0.02 v AAI; p<0.001 v VVI; p=0.001 v DDD-RV and p=0.003 v 
DDD-LV compared to BiV pacing). 
 
 The net augmentation of cardiac output (BiV-AAI) at 18 hours was analysed for 
baseline characteristics that may predict a favourable response to BiV pacing.  The data 
were analysed using a linear regression model with 95% confidence intervals.  The 
baseline characteristics analysed included: QRS duration, valve surgery and electro-
mechanical dyssynchrony.  Figure 24 indicates that there is no link between the 
augmentation of cardiac output and baseline QRS duration (p=0.97; 95% CI -0.15 to 
0.15). 
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Figure 24: The relationship between QRS duration and augmentation of cardiac output 
at 18 hours (p=0.965: 95% CI -0.15 to 0.15). 
 
 Likewise, valve surgery (p=0.61; 95% CI -0.64 to 1.06), mechanical 
dyssynchrony (p=0.486; 95% CI -0.59 to 1.20) and electro-mechanical dyssynchrony 
(p=0.64; 95% CI -0.98 to 0.61) did not predict a favourable response to BiV pacing 
compared to AAI pacing at 18 hours, see figures 25-27.  
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Figure 25: The relationship between valve surgery and augmentation of cardiac output 
at 18 hours, (p=0.61; 95% CI -0.64 to 1.06). 
 
Figure 26:  The relationship between mechanical dyssynchrony and augmentation of 
cardiac output at 18 hours, (p=0.486; 95% CI -0.59 to 1.20). 
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Figure 27:  The relationship between baseline dyssynchrony and augmentation of 
cardiac output at 18 hours, (p=0.64; 95% CI -0.98 to 0.61). 
 
3.2.7 Optimisation of pacing intervals at 18 hours 
 
3.2.7.1 AV optimisation 
 Cardiac output was measured using a FloTrac device for 7 different AV 
intervals ranging from 80ms to 200 ms using 20 ms increments with simultaneous VV 
pacing, see figure 28.  The nominal setting was an AV interval of 120 ms.   
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Figure 28: Cardiac output measured at different AV intervals (nominal setting AVI= 
120ms).  Mean values with standard error of the mean. 
 
A paired T test did not indicate that any that any individual AV delay was 
superior to the norminal setting (p>0.05).  Overall, the nominal setting produced the 
greatest cardiac output and was the optimal AV interval for 40% of patients. The 
optimal range of AV intervals was from 80-140 ms.  A further analysis comparing the 
individual optimal v nominal AV interval did not increase cardiac output (5.3±0.7 
L/min v 5.1±0.7 L/min, p=0.19 respectively).    
The patients enrolled in this study had a PR interval <200 ms with the exception 
of one individual.  After surgery and in the presence of inotropes, AV conduction may 
be enhanced, reducing the range of AV intervals available for BiV pacing.  The elevated 
heart rate after surgery also had a dynamic effect on reducing diastole, which again 
limited the options of AV optimisation, see figure 29.   
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Figure 29:  Heart rate during the trial, at baseline after surgery and 6 and 18-hours. 
Mean ±SEM. 
 
In this study, only 4 subjects were able to receive BiV pacing with an AV 
interval up to 200ms because of fusion with the intrinsic QRS complex. 
 
3.2.7.2 VV optimisation 
 Optimisation of VV intervals were conducted over a range from -40 to +40 ms 
in 20 ms increments (-ve indicating LV pre-activation).  The AV interval was set at 120 
ms, to prevent fusion with the intrinsic QRS complexes.  LV pre-activation by 40 ms 
yielded the greatest augmentation of cardiac output but this did not reach statistical 
significance compared to the nominal setting of simultaneous LV and RV pacing 
(VV=0), see figure 30.   
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Figure 30: Cardiac output measured at different VV intervals (nominal setting VV= 
0ms).  Mean values with standard error of the mean. 
    
However, the optimal VV interval did produce a small but significant 
improvement in cardiac output compared to the nominal setting.  Optimisation of the 
VV interval produced a 4% increase in cardiac output, (5.7±1.6 v 5.5±1.7 L/min 
respectively; p=0.005).  77% of patients benefited from LV pre-activation.  The optimal 
setting was LV pre-activation by 20 ms for 62% of patients.     
 
3.2.8 Comparison of PA catheter and FloTrac 
 271 measurements of cardiac output were collected simultaneously from a PA 
catheter and the FloTrac device, during the haemodynamic studies at baseline, 6 hours 
and 18 hours after surgery.  Measurements were collected from 24 patients.  The 
principal exclusion was the peri-operative insertion of an intra-aortic balloon pump 
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(n=9), which is incompatible with the FloTrac sensor.  The data is illustrated in figure 
31.  A fair correlation is observed between the two devices with a Pearson’s correlation 
co-efficient r=0.75 (p<0.001). 
Figure 31: Linear correlation between measurements of cardiac output obtained from a 
PA catheter and FloTrac sensor.  Pearson’s correlation co-efficient r=0.75 
(p<0.001). 
 
 A second analysis was then conducted using the Bland-Altman method.  The 
bias between the two methods was - 0.33 L/min, with the FloTrac device tending to 
over-estimate the cardiac output compared to the PA catheter.  The precision of the 
FloTrac sensor (combined standard deviation) was 1.1 L/min, see figure 32.  
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Figure 32: Bland-Altman analysis of cardiac output measured using a PA catheter 
compared to the FloTrac sensor.  Bias=-0.33 L/min ±2.2 L/min, 95% 
confidence interval (±2SD).  
 
 The percentage error was 42.5% using the method described by Critchley and 
Critchley and was outside of the acceptable threshold of 28.3% (164).   
Another analysis was performed using only measurements obtained from 
thermodilution catheters (n=77 measurements).  Using the same method, the bias was -
0.76 L/min with the FloTrac device recording a higher output compared to the PA 
catheters.  The precision was 1.2 L/min and the co-efficient of variation was still outside 
the recommended reference range at 43.0%, see figure 33.  
 
-4 
-3 
-2 
-1 
0 
1 
2 
3 
0 2 4 6 8 10 
D
if
fe
re
n
ce
 (
P
A
C
-F
lo
tr
a
c)
  
L
/m
in
. 
Mean Cardiac output (PAC:Flotrac) L/min. 
2x SD 
Bias 
2x SD 
127 
 
Figure 33:  Bland-Altman analysis of cardiac output measured using thermodilution PA 
catheters compared to the FloTrac sensor.  Bias=-0.76 L/min ±2.4 L/min, 
95% confidence interval (±2SD). 
 
 
3.2.9 Renal function 
Estimated glomerular filtration  rate (eGFR) was measured before surgery and 
on admission to cardiac ITU and at 24 hours, 48 hours and 72 hours after the operation.  
Baseline chronic kidney disease score (CKD) was similar in both groups: 2.2±0.9 and 
1.9±0.6, p=0.28 in groups 1 and 2 respectively.  One patient in group 1 and 2 patients in 
group 2 required haemofiltration in the cardiac ITU, (p=0.55).   Renal function was 
similar in both groups throughout the trial, see figure 34.  
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Figure 34:  Renal function (eGFR) before and after cardiac surgery (mean±SEM).    
 
3.2.10 Ventilation 
 The duration of ventilation was similar in both groups, survival analysis (log 
rank) p=0.85, see figure 35. The majority of patients were extubated within 24 hours.  
The patient who required emergency re-sternotomy for tamponade required 110 hours 
of ventilation and one other patient in the BiV group was slow to wean and required 64 
hours of ventilation.  Mean duration of ventilation was 12.9±13.6 hours v 17.9±24.9 
hours in group 1 v 2 respectively. 
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Figure 35: Kaplan-Meier curve for the duration of ventilation in both treatment groups- 
log rank p=0.85.  
  
3.2.11 Inotrope infusions 
Both enoximone and milrinone were used after cardiac surgery.  The average 
duration of using a phosphodiesterase inhibitor was similar in groups 1 and 2, 37.5±31.2 
hours v 56.5±60.3 hours respectively (p=0.24).  Likewise, biventricular pacing did not 
influence the duration of noradrenaline, 53.1±36.9 hours v 53.4±62.5 hours respectively 
(p=0.98).  Correcting the total dose for body mass did not affect the outcome (group 1 v 
group 2): enoximone- 3.5±1.8 mg/kg v 5.0±3.2 mg/kg (p=0.25); milrinone- 0.6±0.6 
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mg/kg v 0.6±0.36 mg/kg (p=0.99) and noradrenaline- 0.3±0.5 mg/kg v 0.3±0.4 mg/kg 
(p=0.97). 
 
3.2.12 NT-pro-Brain Natriuretic Peptide 
 Plasma was collected at baseline, after bypass surgery and at 24hours, 48 hours 
and 72 hours after the operation.  The baseline measurement of NT-pro-BNP was 
similar in both groups: group 1 v 2 (2023±6083 pg/ml v 2950±4205 pg/ml; p=0.75 
respectively).  The change in NT-pro-BNP was analysed in both groups (figure 36).  
Overall, biventricular pacing did not affect NT-pro-BNP compared to standard post-
operative pacing. 
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Figure 36: Change in NT-pro-BNP compared to baseline measurements in both 
treatment groups. 
   
(Median values analysed using Wilcoxon Signed Rank Test). 
 Likewise, there is no clear correlation between baseline NT-pro-BNP and the 
duration of level 3 care for both groups, see figure 37. 
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Figure 37: Relationship between baseline NT-pro-BNP and the duration of level 3 care- 
Pearson’s ranking co-efficient=0.07.  
 
 
3.2.13 Cardiac biomarkers 
 Cardiac troponin T (ng/ml) was measured at the same time as NT-pro-BNP.  
Biventricular pacing did not reduce post-operative TnT levels compared to standard 
pacing methods, see table 21.  
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Table 21:  Post-operative troponin T in both pacing groups. 
Time Troponin T(ng/ml) 
Group 1 Group 2 p 
Pre-op 0.05 ±0.01 0.21 ±0.66 0.26 
Post-op 0.70 ±0.48 0.82 ±0.79 0.66 
24 hours 0.60 ±0.28 0.84 ±0.70 0.28 
48 hours 0.37 ±0.21 0.46 ±0.51 0.59 
72 hours 0.29 ±0.20 0.63 ±0.70 0.13 
 
3.2.14 Complications (arrhythmias and re-operations) 
After cardiac surgery, 16 patients developed atrial fibrillation (8 cases in both 
groups).  The arrhythmias were observed after 24 hours and did not affect the pacing 
protocols.  6 patients were chemically cardioverted with amiodarone (4 patients in 
group 1 and 2 patients in group 2) and one patient in each group required an electrical 
cardioversion.  There were no documented cases of ventricular arrhythmias after 
surgery.  Only one patient had transient second degree heart block (Mobitz type II) after 
aortic valve surgery but no patients required permanent bradycardia pacing. 
One patient required a re-opening of the sternum after surgery for cardiac 
tamponade and removal of blood clots with subsequent haemofiltration.  This was not 
related to the temporary pacing wires implanted during surgery.  A second patient 
developed an unstable sternum that required re-wiring on day 10 after the original 
operation.  This patient had been discharged from the ITU and this adverse event did 
not affect the primary endpoint.    Two patients had a stroke and in total 3 patients 
required haemofiltration including the patient who required the emergency re-
sternotomy. 
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3.2.15 Reproducibility 
 Intra-observer reproducibility was calculated for RV and LV pre-ejection 
intervals and TDI measurements of intra-ventricular mechanical delay, (time delay to 
peak velocity in the basal septum and basal lateral wall).  For 10 patients, these 
measurements were repeated and analysed using a co-efficient of variability model. The 
results were compared to published data (95, 142), see table 22. 
Table 22:  Co-efficient of variation (%) for echocardiogram markers of dyssynchrony 
used in this study compared to data published in previous studies. 
Measurement This study Thomas  Chung 
RV pre-ejection interval /ms 13.9 %   
LV pre-ejection interal/ms 12.4%  3.7% 
TDI- septum to lateral wall/ms 30.7% 62.5%  
  
 Intra-ventricular mechanical dyssynchrony was the least reproducible 
measurement of mechanical dyssynchrony, compared to RV and LV pre-ejection 
intervals.  The low reproducibility of this measurement has previously been reported in 
studies analysing the clinical utility of mechanical dyssynchrony (142).  The 
reproducibility of these markers limits their clinical application.  In this study, baseline 
mechanical dyssychrony did not influence the primary endpoint (duration of level3 care 
after surgery) or predict a haemodynamic response to BiV pacing.    
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Chapter 4- Discussion 
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4.1 Control study 
The patients in this control study had preserved LV systolic dysfunction and no 
baseline evidence of dyssynchrony using QRS duration or markers of mechanical 
dyssynchrony.  After on-pump cardiac surgery, the diastolic filling time was reduced by 
23% and all patients developed paradoxical motion of the inter-ventricular septum.   
Although only minor changes in mechanical dyssynchrony were observed on the 
post-operative echocardiogram, dyssynchrony was not assessed in the immediate post-
operative period.  During this period, inotropes and the deleterious effects of RV pacing 
may have resulted in LV inefficiency and BiV pacing rather than dual chamber RV 
pacing may have been beneficial.   
This study was designed to give an insight into mechanical events after on-pump 
bypass surgery.  Patients with preserved LV function and without baseline 
dyssynchrony were selected, to see if dyssynchrony developed after cardiopulmonary 
bypass.  This would have important implications and support the hypothesis that BiV 
pacing may be beneficial post-bypass, even in patients without baseline dyssynchrony.   
The sample size was limited in this study and on reflection a larger sample of 
patients would have offered reassurance that a type 2 error had not been observed.  This 
study was designed and approved as a major amendment to the main trial and timescale 
limited recruitment into this trial.  The data collected from the post-operative 
echocardiogram was also limited.  The recent sternotomy limited the image quality and 
patient co-operation with a detailed imaging protocol.  The echocardiographic protocol 
was therefore adapted to focus on mechanical dyssynchrony, which was obtained in all 
patients who agreed to the post-operative scan.                 
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Despite these limitations, analysis of the data for the impaired LV study 
supported the finding of the control study.  In the main study, there were no major 
changes in mechanical dyssynchrony after cardiopulmonary bypass.  However, the post-
operative echocardiogram was performed after stopping the temporary pacing and 
inotropes, which are potential causes of dyssynchrony. 
On reflection, a TOE would have allowed assessment of peri-operative 
dyssynchrony using the different pacing modes.  However, in the early post-operative 
period (<6 hours), acute resynchronisation with BiV pacing did not increase cardiac 
output compared to atrial-inhibited or dual chamber pacing.   
 
4.2 Main study 
4.2.1 Recruitment 
 This research trial was successfully completed over an 18 month period.  
Initially patients were recruited from the Cardiac Centre at the University Hospital of 
Wales, Cardiff.  The initial recruitment was limited and to achieve the required sample 
size, patients were also recruited from the Cardiac Centre at Morriston Hospital, 
Swansea.    
There were several reasons why recruitment was limited at the start of the trial.  
This included limited numbers of patients with heart failure receiving cardiac surgery, 
technical problems with operating equipment/sterile packs and the availability of ‘off-
pump’ bypass surgery.  In total, 74 patients were invited into this trial, 6 patients 
declined participation, 6 patients had off-pump surgery and 7 patients did not have an 
operation.  55 patients provided written consent and 38 patients completed the trial.   
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The recruitment rate was approximately 50% (38/74) and lower than our 
anticipated rate of 65-70%.  The logistics of trying to attend operations at two sites 
limited recruitment.  3 patients provided consent and were subsequently not included in 
the final analysis and a further 6 were not enrolled because of conflicts in the operation 
schedule.   
 
4.2.2 Echocardiography and dyssynchrony 
 A transthoracic echocardiogram was performed on all patients entering the 
research trial.  However, only 2 patients received a dobutamine stress echocardiogram 
for viability, which was part of the original trial protocol, and 2 patients had a PET scan.  
There were several reasons for the limited number of dobutamine scans including: 
patients with unstable coronary artery disease (n=3); concomitant valvular heart disease 
(n=15); left main or proximal LAD disease (n=9) and pre-operative intra-aortic balloon 
pump (n=5).  The STICH sub-study also reported difficulty in performing viability 
studies with only 601/1212 patients receiving an assessment which included 280 
dobutamine stress echocardiograms (177).  In our trial, the attending Consultant Cardiac 
Surgeon and/or Cardiologist made the final clinical judgement on whether a viability 
assessment was required before surgery.    
 Despite the limitation of performing dobutamine stress echocardiography, all 
patients received a transthoracic echocardiogram before and after surgery.  15 patients 
were found to have mechanical dyssynchrony on the pre-operative echocardiogram.  
The haemodynamic data showed no association between baseline dyssynchrony and 
response to BiV pacing.  There are several explanations for this result.  Firstly, the total 
sample size was limited and 74% of patients had QRS duration <120 ms.  Secondly, 
139 
 
after surgery all patients may develop mechanical dyssynchrony from RV pacing or 
alterations in loading conditions that would not necessarily respond to BiV pacing.  
Thirdly, the study by Chung et al (95) reported that no single echocardiographic marker 
of dyssynchrony was sufficiently robust to predict a response to BiV pacing to be used 
in routine clinical practice.  
 Although Chung’s study was published in 2008, a more recent publication in 
2013 studying radial strain and TDI time delay in regional deformation, also failed to 
predict a response to BiV pacing (ECHO-CRT) (108).  Patients received optimal 
medical therapy and had QRS duration <130 ms.  This study was prematurely 
terminated at 19 months follow up on the grounds of futility and there was an 
association between BiV pacing and an increase in mortality.   
In summary, the data to support BiV pacing in patients with QRS duration <120 
ms is limited to small, single-centre studies and it has not been found to be beneficial in 
multi-centre, randomised, control trials.  The data from BiV studies after cardiac 
surgery would also suggest that QRS duration >120 ms is required to observe a 
haemodynamic response to BiV pacing (129, 137).  A prolonged QRS duration (>120 
ms) is also required for post-operative permanent BiV pacing to observe LV 
remodelling and reduced mortality (138).      
            
4.2.3 Surgical protocol 
 This study was conducted at two cardiac centres and 9 cardiac surgeons enrolled 
patients into this trial.  Despite variations in surgical and anaesthetic practice, all 
patients had on-pump bypass surgery and received 6 pacing wires as defined in the 
protocol.  My initial plan was to recruit patients from only 1 centre to reduce 
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confounding factors but two centres were required to achieve the desired sample size.  
On reflection, recruiting patients scheduled for revascularisation only and not valve 
operations may have been desirable.  However, patients are more likely to require 
pacing after aortic valve surgery and therefore, this group of patients merited 
investigation. 
There were subtle variations in the choice of post-operative inotropes but in 
general, all patients received a phosphodiesterase inhibitor in combination with 
noradrenaline.  Thermodilution catheters were used at the University Hospital of Wales, 
Cardiff but the cardiac centre at Morriston Hospital used the continuous cardiac output 
PA catheter.  Unfortunately, clinical governance issues prevented standardising the PA 
catheter.  However, the same Flotrac/Vigelio system was used in both centres.  
 
4.2.4 Primary endpoint 
The duration of level 3 was used as the primary endpoint.  Although other 
studies have reported the total duration of ITU stay, we thought that the duration of 
level 3 care was a more robust and clinically relevant endpoint.  It is based on a 
patient’s requirement for multi-organ support and invasive ventilation.  The duration of 
level 3 care has a clear definition and is not influenced by logistical issues including the 
availability of beds on step down units or portering services.    
For the majority of patients 30/38 (80%), the primary endpoint was achieved 
after extubation and then successful weaning to a single inotrope or vasopressor.  For 
eight patients, the primary endpoint was reached after extubation. This small cohort of 
patients had baseline hypertension and therefore minimal requirements for a 
vasoconstrictor to be combined with a phosphodiesterase inhibitor.  There was a skewed 
141 
 
distribution with the majority of patients reaching the endpoint within 48 hours but a 
small number of patients required prolonged multi-organ support.  This included one 
patient requiring an emergency re-sternotomy for tamponade with subsequent acute 
renal failure requiring haemofiltration, one patient who required prolonged inotropic 
support and haemofiltration and one without haemofiltration. 
The results from this trial are similar to the findings reported by Eberhardt (130) 
and Evonich (132) with biventricular pacing having no net effect on the duration of ITU 
admission compared to other pacing modes.   
The trial by Pokushalov (138) did report a 1.4 day reduction in ITU stay with 
biventricular pacing compared to standard post-operative pacing.  However, the 
duration of ITU stay was longer in Pokushalov’s study (CRT group: 2.5±0.5 days v no 
CRT: 3.9±0.6 days; p<0.001) compared to this trial, 22.0 hours (IQR: 16.0-66.5 hours) 
and 37.5 hours (IQR: 16.3-55.0 hours) in group 1 and 2 respectively (log-rank p=0.58) 
and the trials by Eberhardt (130) and Evonich (132).  This may be due to variations in 
the description of the primary endpoint.  However, there were no haemodynamic studies 
to explain the significant reduction in ITU admission with biventricular pacing in 
Pokushalov’s trial.   
 
4.2.5 Haemodynamic data 
 Haemodynamic data were collected from all patients that were enrolled into 
this study.  Only one patient was excluded from the trial because we were unable to 
float a PA catheter.  There were no complications related to the insertion of a PA 
catheter or the additional pacing wires.  The initial haemodynamic studies showed that 
biventricular pacing was not superior to the other pacing methods with the exception of 
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VVI pacing.  However, at 18 hours biventricular pacing was found to be superior to all 
other pacing modes.  There are several potential explanations for this finding.   
 Firstly biventricular pacing is usually performed in patients taking optimal 
doses of heart failure medications including beta blockers.  However after cardiac 
surgery, beta blockers are temporarily discontinued.  In addition, patients are prescribed 
inotropes, which counteract the beneficial effect of beta-blockade and also increase 
heart rate. Finally, immediately after surgery patients are hypovolaemic, hypothermic 
and ventilated.  These factors may reduce the clinical benefit of biventricular pacing 
compared to the other pacing modes.   
 At 18 hours, the majority of patients were extubated and the dose of inotropes 
was minimal.  There was also a net reduction in heart rate at 18 hours compared to 
baseline (baseline: 100.4±15.9 b.p.m v 18 hours: 94.2±9.5 b.p.m; p<0.001).  This may 
explain why biventricular pacing was observed to be beneficial only at 18 hours 
compared to other standard pacing modes, figure 29. 
 In context, in the absence of diabetes, pre-operative arrhythmia and heart 
block on separation from cardio-pulmonary bypass, only 2.6% require temporary pacing 
after cardiac surgery (123).  However, the risk of a serious complication from temporary 
pacing wires is low (0.04%).  In this high-risk surgical cohort, atrial synchronous pacing 
should be considered because of the significant reduction in cardiac output (>20%) with 
VVI pacing.  If prolonged ventricular pacing is likely because of pre-operative 
HIS/Purkinje fibre disease or the nature of the operation (180, 181), then temporary BiV 
pacing should be considered.    
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4.2.6 Optimisation of pacing intervals 
 Pacing intervals were optimised at 18 hours using a FloTrac haemodynamic 
monitor.  These measurements were taken after performing a full set of haemodynamic 
measurements in 5 different pacing modes at 18 hours using a PA catheter and a 
FloTrac device.   
 The FloTrac monitor was used because it rapidly recorded acute changes in 
cardiac output.  The disadvantage of using a PA catheter was the time required to 
perform 3-5 separate haemodynamic measurements of cardiac output using 
thermodilution or the time required for the continuous cardiac output monitor to 
calibrate after each change in an AV or VV interval. 12 separate measurements of 
cardiac output were required per patient for the AV and VV optimisation protocol. 
 The limitation of using a FloTrac device was that all patients with an intra-
aortic balloon pump were excluded from the optimisation study.  The FloTrac device 
cannot be calibrated in patients with aortic counter-pulsation.  Therefore, 9 patients 
were excluded from the optimisation protocol.  Optimisation of the VV interval was 
feasible in all patients.  Left ventricular pre-activation was found to be beneficial 
compared to nominal settings.  The optimal VV interval produced a 4% augmentation 
of cardiac output (p=0.005).  Although statistically significant, the clinical utility of this 
small improvement in cardiac output is open to interpretation. 
 AV optimisation was limited because most patients had a normal PR interval 
on their resting ECG.  This limited the range of AV delays that would allow 
biventricular pacing, without fusion with intrinsic rhythm.  Only two patients could be 
paced with an AV interval of 200 ms.  The data suggest that an AV interval of 120 ms is 
optimal and there is an acute decrement in cardiac output with an AV interval <100 ms 
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or >180 ms.  However this did not reach statistical significance.  This may impart be 
explained by the limited sample size.   
 
4.2.7 FloTrac system 
 The arterial wave form analysis device (FloTrac, Edwards Lifesciences) was 
easy to use and rapidly reported acute changes in cardiac output, for example when VVI 
pacing was assessed during the haemodynamic studies.  One of the major disadvantages 
of this technology is that the device is incompatible with intra-aortic balloon pumps, 
which are frequently used in high risk patients. 
 The Bland-Altman analysis revealed a small bias between the PA catheter and 
the FloTrac device (0.33 L/min) but a wide 95% confidence interval ±2.2 L/min.  The 
percentage error (42.5%) was also in excess of the acceptable limit of <30%.  The poor 
correlation between these two methods of assessing cardiac output, along with the 
limitations of the FloTrac device suggests that the PA catheter remains a better option 
for monitoring high-risk patients in ITU after surgery. 
 However, it is important to highlight that PA catheters carry a 1-2% risk of 
significant complications including pulmonary artery or tricuspid valve injury (161).  In 
addition, the continuous cardiac output catheter is slow to respond to acute changes in 
cardiac output and the thermodilution method of assessing cardiac output is less reliable 
immediately after surgery, in the context of systemic hypothermia (161).   In routine 
clinical practice, the risks and benefits of invasive haemodynamic monitoring need to be 
carefully considered on an individual basis.  
 An alternative method of assessing cardiac output and volume status after 
cardiac surgery is the transoesophageal Doppler.  Previous studies have reported that 
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peri-operative Doppler guided volume replacement reduces the length of hospital 
admission by 2.5 days (18%) (p=0.02) and reduces the incidence of gut mucosal 
hypoperfusion by 8-fold (182, 183).  However, this technology has only been 
investigated in elective cardiac patients with preserved function and not in patients with 
severe LV dysfunction.  This technology has a good safety record with minimal risk of 
complications (184).  Future studies should consider evaluating this technology to 
optimise fluid status and inotropes in the cardiac ITU.  This device may also be helpful 
to optimise the AV and VV pacing intervals and is compatible with an intra-aortic 
balloon pump. 
 
4.2.8 Limitations 
Recruiting patients into this trial was challenging because of the requirement for 
additional pacing wires and a PA catheter.  38 patients completed this trial, which 
represents the third largest published study of temporary biventricular pacing after 
cardiac surgery. The largest study (n=178) did not publish acute haemodynamic data. 
The primary endpoint was survival at 18 months between patients receiving 
biventricular pacing compare to a control group. 
The average duration of biventricular pacing in group 1 was 22.7±8.8 hours, 
which on average was 12.3±28.4 hours less than the duration of level 3 care (p=0.07).  
The temporary biventricular pacing was frequently discontinued on the morning after 
surgery at the request of the attending surgeon, when the patient had a minimal 
requirement for inotropes.  Although the patients were haemodynamically stable, they 
had not reached the primary endpoint.  It is possible that continuation of biventricular 
pacing may have altered the primary endpoint.  However, it is unlikely that continuation 
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of biventricular pacing beyond this point would have changed the clinical outcome after 
the operation.   
It is also difficult to comment on whether a prolonged duration of temporary 
biventricular pacing would have reduced the incidence of post post-operative atrial 
fibrillation.  8 patients in the biventricular pacing group developed atrial fibrillation, the 
peak of which was observed on post-operative day 2-3.  
The duration of AV/VV optimised pacing was limited to 4.8±8.8 hours before 
discontinuation of biventricular pacing.  It is possible that a longer duration of 
optimised biventricular pacing may have been beneficial with respect to the primary 
endpoint.  However the beneficial effects of biventricular pacing were only evident at 
18 hours and not at baseline or 6 hours.  Finally, performing the optimisation protocol 
was time-consuming.  It would have been difficult to keep inotropic concentrations 
constant, to allow for an accurate comparison cardiac output at baseline or 6 hours.  At 
18 hours most patients were extubated and prescribed low concentrations of inotropes, 
which made performing an optimisation protocol feasible.  
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Chapter 5- Summary 
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5.1 Conclusions 
The main findings of this thesis are:  
 Patients with preserved LV function (EF >45%) have minimal evidence of 
mechanical dyssynchrony.  After on-pump cardiac surgery, only subtle changes 
are observed, including a 23% reduction in diastolic filling time and a 
paradoxical motion of the inter-ventricular septum- section 3.1. 
 Intra and inter-ventricular mechanical delay were not adversely affected by on-
pump cardiac surgery in patients with severe LV systolic dysfunction- section 
4.2.2. 
 Temporary biventricular pacing is feasible and safe after cardiac surgery.  The 
most common side-effect is phrenic nerve stimulation which was noted in 16% 
(3/19) patients and can usually be resolved by reprogramming the LV pacing 
voltage- section 3.2.14. 
 Despite the routine use of pacing wires after cardiac surgery, only 1 patient 
developed transient second degree AV block, after an aortic valve replacement- 
section 3.2.14. 
 The primary endpoint, ‘duration of level 3 care’ was not influenced by 
temporary BiV pacing.  Previous trials have reported similar results even with 
96 hours of BiV pacing (130, 132)- section 3.2.5. 
 Baseline mechanical dyssynchrony did not predict a response to temporary BiV 
pacing in patients with severe LV systolic impairment- section 3.2.6. 
 Temporary BiV pacing improved cardiac output at 18 hours but not at baseline 
or 6 hours after surgery compared to all other pacing modes with the exception 
of VVI pacing.  This may in part be explained by a reduction in heart rate at 18 
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hours compared to baseline measurements; 6.2 b.p.m reduction observed at 18-
hours v baseline (p <0.001)- section 3.2.6. 
 VVI pacing uncoupled AV synchrony and was detrimental to haemodynamic 
function compared to all other pacing modes in this trial, reducing cardiac output 
by up to 19%- section 3.2.6. 
 VV optimisation increased cardiac output by 4% but this small increment may 
be of limited clinical value.  77% of patients benefitted from LV pre-activation 
but no individual setting was found to be superior to the nominal setting 
(RV=LV)- section 3.2.7. 
 AV optimisation was not beneficial but all except one patient had a normal PR 
interval (<200ms) on the pre-operative ECG- section 3.2.1. 
 BiV pacing did not influence: the duration of ventilation or inotropes; the total 
dose of inotropes; or post-operative markers of myocardial injury including 
troponin T (TnT) and NT pro-brain natriuretic peptide (NT-pro-BNP)- sections 
3.2.10 to 3.2.13. 
 Equal numbers of arrhythmic events were observed in both treatment groups 
(BiV v standard pacing).  The episodes of atrial fibrillation occurred after 
discontinuation of the temporary BiV pacing- section 3.2.14. 
 All patients survived to 30-days after surgery and were successfully discharged 
from hospital.  Two patients had a cerebro-vascular event.  One patient required 
an emergency re-sternotomy for bleeding, which significantly prolonged there 
duration of level 3 care- section 3.2.14. 
 There were no adverse events from using PA catheters or LV pacing wires in 
this trial.  Only one set of LV wires was implanted outside the region of the first 
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obtuse marginal branch of the circumflex artery because of LV scar tissue- 
sections 3.2.3 and 3.2.14. 
 The PA catheters were usually removed on post-operative day 1 to allow the 
patient to sit out of bed.  This limited the time frame to collect haemodynamic 
data to less than 24 hours- section 3.2.6. 
 The duration of BiV pacing was 12.3±28.4 hours less than the duration of level 3 
care in group 1, (p=0.08).  BiV pacing was only prematurely discontinued at the 
request of the surgical team.  In most cases, the inotropic requirements were 
minimal when the BiV pacing was stopped and this is unlikely to influence the 
transition from level 3 to level 2 care- section 3.2.5. 
 The FloTrac/Vigelio system uses pulse-contour analysis to calculate cardiac 
output from the radial arterial tracing.  This method is simple to use and rapidly 
reports acute changes in cardiac output but the percentage error was 42.5% and 
outside an acceptable limit of agreement with the PA catheter- reference <28.3% 
(164)- section 3.2.8. 
 Future studies should target patients with broad QRS durations, and consider 
pacing at the site of latest LV activation.  Future research should also investigate 
the effects of post-operative BiV pacing in patients with atrial fibrillation. 
 
5.2 Future directions 
 This was a challenging and yet rewarding research project.  Recruitment was 
slow at the start of this study.  There were many reasons including: the limited number 
of patients with severe LV dysfunction having cardiac surgery; the prevalence of AF in 
this population and logistical issues, including our supply of temporary BiV pacing 
boxes.  The addition of a second surgical centre and a second pacing box undoubtedly 
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helped with recruitment.  The total number of patients recruited into this study exceeded 
the estimated sample size. 
 
5.2.1 Dyssynchrony 
   Unfortunately, BiV pacing did not influence the duration of level 3 care in this 
study.  The largest study of BiV pacing after cardiac surgery reported that permanent 
epicardial BiV pacing after surgical revascularisation reduced mortality by 16% 
compared to CABG-only (138).  This study recruited patients with a QRS duration 
>120 ms or mechanical dyssychrony, including: inter-ventricular mechanical delay >40 
ms; aortic pre-ejection delay >140 ms or intra-ventricular dyssychrony using TDI.  Most 
patients had a prolonged QRS duration, the mean duration was 139±28ms.   
The trial by Straka et al, included patients with QRS >150 ms or 120-149 ms 
with dyssynchrony on 3D TOE (129).  LV lead position was targeted to the site of latest 
LV activation and the AV and VV pacing intervals were optimised using TOE.  BiV 
pacing increased mean arterial pressure by 5% and cardiac output by 24% compared to 
dual-chamber RV pacing (129). 
These data suggest that patients with a QRS duration >120 ms are more likely to 
benefit from post-operative BiV pacing rather than taking all patients with severe LV 
dysfunction.  This should guide patient selection for future studies of BiV pacing after 
cardiac surgery.  The data to recommend 3D transoesphageal echocardiography to guide 
LV lead positioning is limited but the provisional results appear promising.  Further 
studies to confirm this hypothesis would be welcome.   
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Pre-operative mechanical dyssychrony with a QRS duration <120 ms does not 
appear to influence the post-operative response to BiV pacing.  Selecting patients based 
on QRS duration appears to be the best strategy.   
 
5.2.2 Post-operative AV block 
The number of patients developing second or third degree AV block after 
surgery was limited to one patient.  Overall, the proportion of patients requiring post-
operative pacing is 9%, but the loss of AV synchrony with VVI pacing reduces cardiac 
output by up to 20% (123).   
Therefore, patients with severe LV dysfunction should receive atrial pacing 
wires.  If patients are likely to require post-operative ventricular pacing, BiV pacing 
would be the preferable option.  Patients are more likely to require post-operative 
ventricular pacing after aortic valve surgery or if AV block is present on separation 
from the cardio-pulmonary bypass circuit.   
 
5.2.3 Atrial fibrillation 
 This study followed the pattern of the randomised control trials of BiV pacing 
by recruiting patients in sinus rhythm.  However, in the heart failure population up to 
30% of patients have AF and this sub-group of patients remains under researched.  The 
study by Eberhardt et al, included 12% (n=11) of patients in AF before surgery but this 
sub-group was too small for sub-analysis (130). 
 Patients with paroxysmal AF may spend up to 90% of the time in sinus rhythm 
and permanent BiV pacing may reduce the number and duration of these arrhythmic 
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episodes and promote atrial remodelling (185).  However, there is no clear evidence that 
post-operative BiV pacing reduces the incidence of atrial arrhythmias. This is an area 
that would merit further research. 
 A meta-analysis of heart failure patients in atrial fibrillation who received BiV 
pacing, reported that BiV pacing improved heart failure symptoms and LV remodelling 
(186).  NHYA score improved on average by one point on the NHYA scale and EF by 
10% compared to baseline.  However, heart rate control is important in this group of 
patients to ensure a high percentage of BiV pacing and AV node ablation may improve 
clinical response to BiV pacing v no ablation (RR 0.4; 95% CI 0.28-0.58; p<0.001) 
(187, 188).  Therefore, the elevated heart rate after cardiac surgery may suggest that 
BiV pacing is unlikely to improve cardiac output compared to intrinsic rhythm.  
However, in patients with post-operative AV block, BiV pacing may be beneficial and 
this merits investigation.   
A further consideration is whether the group of patients who receive pulmonary 
vein isolation/AF ablation during surgery may benefit from BiV pacing to maintain 
sinus rhythm.  This may be considered in heart failure patients with prolonged QRS 
durations but there is evidence to suggest that bi-atrial pacing may reduce AF after 
cardiac surgery.   
A study of 220 patients, who had a MAZE procedure with or without valve 
surgery, over-drive bi-atrial pacing reduced incidence of post-operative AF by 3-fold 
compared to right atrial pacing or no atrial pacing (p <0.01) (189).  A study of patients 
with no prior history of AF reported that bi-atrial pacing reduced the occurrence of AF 
after CABG by 3-fold, compared to left or right atrial, or no atrial pacing (p <0.05) 
(190).  Bi-atrial pacing in combination with BiV pacing may prevent post-operative AF 
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and optimise cardiac output, but requesting up to 8 temporary pacing wires after surgery 
may be ‘a bridge too far’, even for a pacing enthusiast!      
 
5.2.4 Haemodynamics 
The requirement for inotropic support is at its highest in the early post-operative 
phase.  The study by Lalu et al, illustrated a nadir in LV stroke work index at 3 hours 
after surgery, that eventually improved by 12 hours (figure 1) (43).  Paradoxically, the 
beneficial effects of BiV pacing were not observed until 18 hours after surgery and the 
mean duration of inotropic support was 48.2±48.3 hours.  Therefore, inotropes and 
intra-aortic balloon counter-pulsation are required to support cardiac output during this 
critical period.    
The trial by Eberhardt et al, reported no reduction in ITU admission or increase 
in cardiac output with BiV pacing compared to conventional pacing modes, after 96 
hours of post-operative BiV pacing (130).  Therefore, the shorter duration of BiV 
pacing is this study is unlikely to have influenced the primary endpoint.  The duration of 
post-operative pacing should be based on the requirements for bradycardia pacing rather 
than haemodynamic support.  There was no evidence that post-operative BiV pacing 
reduced myocardial injury (TNT/NT-pro-BNP) or protected against acute kidney injury 
compared to conventional pacing in Eberhardt’s study or my study.    
These statements are based on the current published literature of post-operative 
BiV pacing, which principally enrolled patients with narrow QRS complexes (<120 
ms).  There is limited data from Straka et al, that BiV pacing may increase cardiac 
output after surgery in patients with QRS durations >120 ms.  Future studies should 
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focus on the haemodynamic effects of temporary BiV pacing in patients with prolonged 
QRS durations (>120 ms).    
       
5.2.5 Pacing intervals 
 Optimisation of the AV and VV pacing intervals was performed at 18 hours 
after surgery.  It was technically difficult to perform AV optimisation because of the 
elevated resting heart rate and the limited range of AV intervals available for 
optimisation.  VV optimisation did yield a small (4%) increase in cardiac output.  In 
routine practice, optimisation of these pacing intervals is unlikely to alter clinical 
outcome with respect to the duration of ITU admission or inotropic support.  This 
process is time consuming and can take up to 1 hour to perform. 
 Only one other study has reported data on AV/VV optimisation after cardiac 
surgery.  Wang et al, reported that optimised BiV pacing increased cardiac output by 
13% (p=0.003) compared to atrial-inhibited pacing in 11 patients, QRS 116±19ms and 
EF <35% (157).  Further studies are required to confirm these findings.   
Optimisation of pacing intervals may be considered for patients who require 
post-operative pacing, extending beyond the first 24 hours after surgery.  There are 
limited data to suggest that optimised BiV pacing may improve cardiac output 
compared to nominal BiV settings.      
 
5.3 Pacing algorithm 
After reading the literature and conducting this trial, I would suggest the 
following algorithm for post-operative BiV pacing, illustrated in figure 38.  
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Haemodynamic studies should be performed at 18 hours to confirm augmentation of 
cardiac output with BiV pacing compared to conventional pacing modes.  At this stage, 
AV/VV optimisation may be considered: if patients have escalating requirements for 
inotropic agents or are likely to require prolonged BiV pacing as a bridge to permanent 
device implantation. 
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Figure 38: Algorithm for post-operative BiV pacing. 
 
Sinus rhythm, EF <35%.  BiV pacing 
 
QRS >120ms. 
OR 
 
High probability of AV block: 
 Pacing during separation from CPB. 
 Aortic valve surgery. 
 Pre-op bundle branch block or 
profound 1
0
 AV block (>300 ms). 
 
 
Consider: 
 AV/VV optimisation. 
 LV lead at site of latest activation. 
 
 
Conventional pacing 
 
 Normal 12-lead ECG. 
 QRS <120 ms. 
 Low risk AV block. 
(see opposite) 
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5.4 Final Summary  
 Biventricular pacing is an established heart failure treatment for patients with 
severe LV dysfunction (EF <35%) and prolonged QRS durations (QRS >120 ms).  The 
beneficial haemodynamic effects of temporary biventricular pacing after cardiac surgery 
are minimal in patients with narrow QRS complexes (QRS <120 ms).  I only observed a 
small (7%) increase in cardiac output with biventricular pacing compared to dual 
chamber-RV and atrial inhibited pacing at 18 hours.  For biventricular pacing to be 
beneficial after surgery, this increment needed to be observed in the first 6 hours after 
the operation. 
 Biventricular pacing could be considered in patients with severe LV impairment 
and QRS duration >120 ms, especially if prolonged pacing is anticipated after cardiac 
surgery.  A nominal AV interval of 120 ms is usually programmed but optimisation may 
produce a further small increment in cardiac output.  The optimal AV delay is variable 
and needs to be defined for each patient although this is a time consuming process. 
 For the majority of patients the standard right atrial and right ventricular leads 
will suffice to treat post-operative AV block which is an uncommon event after isolated 
coronary artery bypass surgery.     
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Appendix A
Consent form for figure 9.  
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